WO2021210686A1 - Coronavirus vaccine - Google Patents
Coronavirus vaccine Download PDFInfo
- Publication number
- WO2021210686A1 WO2021210686A1 PCT/JP2021/015773 JP2021015773W WO2021210686A1 WO 2021210686 A1 WO2021210686 A1 WO 2021210686A1 JP 2021015773 W JP2021015773 W JP 2021015773W WO 2021210686 A1 WO2021210686 A1 WO 2021210686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- protein
- coronavirus
- transmembrane domain
- virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 35
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 57
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 51
- 239000002157 polynucleotide Substances 0.000 claims abstract description 51
- 241000710929 Alphavirus Species 0.000 claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 36
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 101710172711 Structural protein Proteins 0.000 claims abstract description 28
- 101800001631 3C-like serine proteinase Proteins 0.000 claims abstract description 12
- 101800000515 Non-structural protein 3 Proteins 0.000 claims abstract description 12
- 101800004803 Papain-like protease Proteins 0.000 claims abstract description 12
- 101800002227 Papain-like protease nsp3 Proteins 0.000 claims abstract description 12
- 101800001074 Papain-like proteinase Proteins 0.000 claims abstract description 12
- 101800000511 Non-structural protein 2 Proteins 0.000 claims abstract description 10
- 101800000514 Non-structural protein 4 Proteins 0.000 claims abstract description 10
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 8
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 claims abstract description 8
- 101800000512 Non-structural protein 1 Proteins 0.000 claims abstract description 8
- 102000005962 receptors Human genes 0.000 claims abstract description 8
- 108020003175 receptors Proteins 0.000 claims abstract description 8
- 108700010904 coronavirus proteins Proteins 0.000 claims abstract 11
- 239000013598 vector Substances 0.000 claims description 43
- 241000711573 Coronaviridae Species 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 23
- 101710154606 Hemagglutinin Proteins 0.000 claims description 20
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 20
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 20
- 101710176177 Protein A56 Proteins 0.000 claims description 20
- 239000000185 hemagglutinin Substances 0.000 claims description 19
- 230000003053 immunization Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 12
- 229940096437 Protein S Drugs 0.000 claims description 12
- 101710198474 Spike protein Proteins 0.000 claims description 12
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 4
- 108010052285 Membrane Proteins Proteins 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 39
- 150000001413 amino acids Chemical group 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 239000002502 liposome Substances 0.000 description 14
- -1 CD86 Proteins 0.000 description 13
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 12
- 102000035160 transmembrane proteins Human genes 0.000 description 11
- 108091005703 transmembrane proteins Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 241001502567 Chikungunya virus Species 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 241001678559 COVID-19 virus Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 102000045717 human TLR4 Human genes 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 241000710951 Western equine encephalitis virus Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 102000035118 modified proteins Human genes 0.000 description 4
- 108091005573 modified proteins Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010087302 Viral Structural Proteins Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XKEXPKRXNCVBFB-UHFFFAOYSA-N 1$l^{3}-stannacyclohexa-1,3,5-triene Chemical compound C1=CC=[Sn]C=C1 XKEXPKRXNCVBFB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101100377809 Arabidopsis thaliana ABC1K3 gene Proteins 0.000 description 2
- 241000178568 Aura virus Species 0.000 description 2
- 241000231314 Babanki virus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000710946 Barmah Forest virus Species 0.000 description 2
- 241000608319 Bebaru virus Species 0.000 description 2
- 241000231316 Buggy Creek virus Species 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 2
- 102100031726 Endoplasmic reticulum junction formation protein lunapark Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- 241000465885 Everglades virus Species 0.000 description 2
- 241000231322 Fort Morgan virus Species 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 241000608297 Getah virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000710948 Highlands J virus Species 0.000 description 2
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 2
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000231318 Kyzylagach virus Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108050001696 Major intrinsic proteins Proteins 0.000 description 2
- 102000011364 Major intrinsic proteins Human genes 0.000 description 2
- 241000608292 Mayaro virus Species 0.000 description 2
- 241000710949 Middelburg virus Species 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241000868135 Mucambo virus Species 0.000 description 2
- 241000608287 Ndumu virus Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 241000710944 O'nyong-nyong virus Species 0.000 description 2
- 241000868134 Pixuna virus Species 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 101150062156 RBD2 gene Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 101100135806 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PCP1 gene Proteins 0.000 description 2
- 241000608282 Sagiyama virus Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 241000608278 Una virus Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000231320 Whataroa virus Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000054189 human CD80 Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 108010008595 sarcoma-associated antigen S1 Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 108010019924 stannin Proteins 0.000 description 2
- 102000005896 stannin Human genes 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 102100035785 Acyl-CoA-binding protein Human genes 0.000 description 1
- 101710106492 Acyl-CoA-binding protein Proteins 0.000 description 1
- 101710169323 Acyl-CoA-binding protein homolog Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005128 Alkaline Ceramidase Human genes 0.000 description 1
- 108700001266 Alkaline ceramidases Proteins 0.000 description 1
- 108091006987 Ammonia transporters Proteins 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 101000933074 Arabidopsis thaliana Protein C2-DOMAIN ABA-RELATED 4 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 101150078651 Epha4 gene Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000038630 GPCRs class A Human genes 0.000 description 1
- 108091007907 GPCRs class A Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100034551 Glycolipid transfer protein Human genes 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101001059390 Homo sapiens Formin-1 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001014213 Homo sapiens Morphogenetic neuropeptide Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100023758 Leukotriene C4 synthase Human genes 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101100219997 Mus musculus Ccr1 gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102000006243 Neutral Ceramidase Human genes 0.000 description 1
- 241001428748 Ockelbo virus Species 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 101710113369 Putative acyl-CoA-binding protein Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 229940124680 SARS vaccine Drugs 0.000 description 1
- 108091029810 SaRNA Proteins 0.000 description 1
- 108050007079 Saposin Proteins 0.000 description 1
- 102000017852 Saposin Human genes 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 101710147732 Small envelope protein Proteins 0.000 description 1
- 108050006252 Squalene/phytoene synthases Proteins 0.000 description 1
- 102000016651 Squalene/phytoene synthases Human genes 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010087711 leukotriene-C4 synthase Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001167 microscope projection photolithography Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001447 template-directed synthesis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108020003234 urea transporter Proteins 0.000 description 1
- 102000006030 urea transporter Human genes 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present disclosure relates generally to the field of a vaccine and to a method and a composition for treating and/or immunizing against viral infections.
- the present disclosure relates to a vaccine for coronavirus such as SARS-CoV-2 (COVID-19).
- Coronaviruses are a large family of viruses that usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. However, three new coronaviruses have emerged from animal reservoirs over the past two decades to cause serious and widespread illness and death.
- SARS coronavirus SARS coronavirus
- SARS-CoV severe acute respiratory syndrome
- MERS-CoV MERS coronavirus
- SARS-CoV-2 The third novel coronavirus to emerge in this century is called SARS-CoV-2. It causes coronavirus disease 2019 (COVID-19), which emerged from China in December 2019 and was declared a global pandemic by the World Health Organization on March 11, 2020. (https://www.niaid.nih.gov/diseases-conditions/coronaviruses)
- Antibody-dependent enhancement is a mechanism by which some viruses such as dengue virus, feline coronavirus, and HIV, as an alternative strategy, can infect host cells that display Fc receptors and thereby take advantage of anti-viral humoral immune responses. Whether ADE occurs in SARS-Coronavirus infections is controversial, but it has been reported that antibodies against the spike protein of SARS-Coronavirus may cause ADE effect.
- Non-Patent Literature 1 a vaccine scientist at Baylor College of Medicine in Houston, Texas, thinks potential vaccines should be tested in animals first to rule out disease enhancement, before trials move on to humans. He says he understands the reasoning for pushing SARS-CoV-2 (COVID-19) vaccines to human tests quickly, but adds that, because of the possibility that a vaccine could enhance disease, “I’m not sure this is the vaccine you want to do it for”. (Non-Patent Literature 1)
- T he protein/polypeptide disclosed herein include a coronavirus structural protein fused to a signal sequence and/or a transmembrane domain.
- the coronavirus structural protein may be a spike(S) protein, nucleocapsid (N) protein, membrane (M) protein, a small envelope protein (E) or a combination thereof. Specific examples may include S1 and/or S2 subunit of the spike protein and especially, receptor binding domain of the S1 subunit.
- the present disclosure relates to a novel polynucleotide encoding the above discussed novel antigenically-active proteins/polypeptides capable of inducing protection against coronaviruses.
- the present disclosure relates to a novel alphavirus replicon that can express the above discussed antigenically-active protein/polypeptide.
- the alphavirus replicon includes polynucleotide such as RNA encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polynucleotide encoding the above-discussed antigenically active protein/polypeptide as a gene of interest.
- the present disclosure relates to a vaccine comprising the above discussed polypeptide or polynucleotide.
- the present disclosure provides a vaccine comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, and a polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or transmembrane domain.
- the vaccine can be used for preventing and/or treating a subject from coronavirus infection.
- the present disclosure relates to a method for immunizing, preventing or treating a subject from coronavirus infection comprising administering an effective amount of the above-discussed polypeptide or polypeptide to the subject in need thereof.
- the present disclosure relates to use of the above-discussed polypeptide or polynucleotide for the manufacture of a medicament.
- a construct of an alphavirus replicon Full length VEEV TC-83 vector of the construct C including SS1-RBD-GS-IgG4-CH 3 (linker)-GS-TM1 produced in Example 3. Expression of RBD in HEK293T cells transfected with the alphavirus replicon plasmid vectors prepared in Example 3. Antibody titer against COVID-19 Spike protein in mice sera on day 14 and day 35 immunization with the alphavirus replicon particles prepared in Example 4.
- coronavirus is meant to refer to single-stranded, positive-sense RNA viruses that belong to the family, Coronaviridae.
- Exemplary Coronaviridae viruses include but are not limited to SARS-Cov, MERS-Cov and SARS-CoV-2 (COVID-19).
- SARS-CoV-2 (COVID-19) may include known and unknown mutants.
- Known mutants may include COVID-19 E484K_N501Y_K417T mutant (Brazil Strain Mutant), E484K_N501Y_K417N mutant (South African Mutant) and E484K mutant.
- the coronavirus genome encodes numerous non-structural proteins and four major structural proteins including the spike (S), nucleocapsid (N), membrane (M) and small envelope (E).
- Spike (S) protein a large envelope glycoprotein, is composed of S1 and S2 subunits.
- the “Receptor-binding domain (RBD)” is located in the S1 subunit.
- RBD Receptor-binding domain
- Preferable example of the structural protein used herein is coronavirus RBD.
- Spike protein, S1 and S2 subunits of the spike protein and RBD of COVID-19 and its mutants have been identified and published (Wrapp et al., Science 10.1126/science.abb2507(2020), Z. Wang et al., (preprint) bioRxiv 2021.01.15.426911; doi: https://doi.org/10.1101/2021.01.15.426911).
- Coreonavirus structural protein used herein may be a naturally occurring virus structural protein or a modified protein thereof.
- the modified protein may be a fragment of the naturally occurring virus structural protein.
- the modified protein has at least 70%, 75%, 80%, 85%, 90%, 95% or 98% amino acid sequence identity to a naturally occurring viral structural protein or its fragment.
- the modified protein is a mutant where at most 10% of the amino acids are deleted, substituted, and/or added based on a naturally occurring viral envelope protein or its fragment.
- transmembrane domain is a protein derived either from a natural or from a synthetic source. Where the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein. In one aspect, the membrane-bound or transmembrane protein is a protein heterologous to COVID-19.
- membrane-bound or transmembrane proteins may include the alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154; toll-like receptors (TLR) such as TLR1-TLR10 in human and TLR1-TLR9, TLR11-TLR13 in mouse; interleukin (IL) receptors such as IL-1-28 receptor, RANTES receptors (CCR1, CCR3, CCR5), MIP-1 receptor, PF4 receptor, M-CSF receptor and NAP-2 receptor belonging to GPCR chemokine receptor; hemagglutinin (HA).
- the membrane-bound or transmembrane protein is a protein derived from COVID-19, such as COVID-19 spike protein.
- transmembrane proteins may also include the followings: 5-Lipoxygenase-Activating Protein, ABC Transporters, ACBP, Amyloid beta (A4), Bcl-2 Inhibitors, BNIPs, CAAX protease, Cytochromes P450, E-NPPs, EPHA1, EPHA2, EPHA3, EPHA4, Fatty Acid Desaturases, Gamma secretase, Glucose transporter, Glycophorins, GPCR, HER2/ErbB2, HER3/ErbB3, HER4/ErbB4, HSD-11 ⁇ , Hypoxia-induced Proteins, Immunoglobulins, Insulin receptor, Integrins, Ion channel, MAPEG, MFS, MinK Family, MPPs, Peptidase AD, Peptidase Family M48, Peptidase MA, Protein Jagged, Receptor-type Kinases, SNARE Complex, Sulfatases, TNF receptor, Transmembrane Proteins 14, Transporter, TROBP
- monotypic/peripheral proteins that attached to the lipid bilayer or other integral proteins and peptide may also be used as transmembrane proteins.
- Examples may include Alpha/Beta-Hydrolase, Annexins, Bet V1-Like Protein, C1 Domain-Containing Protein, C2 Domain-containing Protein, CoA-Dependent Acyltransferases, CRAL-TRIO Domain-Containing Protein, DNase I-like protein, Fibrinogen , FYVE/PHD Zinc Finger Protein, Galactose-Binding Domain-Like Protein, Glycolipid Transfer Protein, Immunoglobulin-Like Superfamily (E Set) Protein, Lipocalin, Lipoxygenase, PGBD superfamily, PH Domain-Like Protein, Phosphatidylinositol 3-/4-Kinase, PLC-like Phosphodiesterase, Phosphotyrosine Protein Phosphatases II, P
- transmembrane domain used in the present disclosure includes at least transmembrane region(s) of the membrane-bound or transmembrane protein.
- the transmembrane domain may also include juxtamembrane domain (JMD) and/or cytoplasmic tail of the membrane-bound or transmembrane protein.
- JMD juxtamembrane domain
- cytoplasmic tail of the membrane-bound or transmembrane protein
- the transmembrane domain in some embodiments is synthetic.
- the synthetic transmembrane domain comprises predominantly hydrophobic residues such as leucine and valine.
- a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain.
- Preferable transmembrane domain may be those derived from influenza virus hemagglutinin (HA), CD80, Toll-like receptor 4(TLR4) or COVID-19 spike protein.
- Specific examples may include a protein consisting of the flexible juxtamembrane region or flexible linker, the transmembrane domain and the cytoplasmic tail of Influenza virus hemagglutinin "HA (flexible-TM-Cyt)"; a protein consisting of transmembrane domain and cytoplasmic tail of human CD80; a protein consisting of transmembrane domain(TM) and Toll/interleukin-1 receptor domain (TIR), and a protein consisting of the juxtamembrane domain (JMD) and TM of COVID-19 Spike (S).
- signal sequence (sometimes referred to as signal peptide, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide) is a polynucleotide or polypeptide, depending on the context. Signal sequence is from about 9 to 200 nucleotides or 3-70 amino acids in length that, optionally, is incorporated at the 5' or N-terminus of the coding region or the protein. Some signal sequences are cleaved from the protein, for example by a signal peptidase after the proteins are transported to the desired site.
- the signal sequence of IL-2 especially human IL-2 may be employed.
- the signal sequence of the COVID-19 spike protein may be employed.
- the coronavirus structural protein, the transmembrane domain and/or the signal sequence may be directly or indirectly fused. In one embodiment, one or two linkers may intervene between them.
- coronavirus structural protein, the transmembrane domain and/or the signal sequence can be truncated and replaced by short linkers.
- the coronavirus structural protein, the transmembrane domain and/or the signal sequence include one or more peptide linkers.
- a short linker consists of from 2 to 25 amino acids (e.g. 2, 3, 4, 5 or 6 amino acids). Usually, it is from 2 to 15 amino acids in length, such as SG, GS, SGG, GGS SGSG and TRGGS. In certain circumstances, the linker can consist of only one amino acid, such as glycine(G), serine (S) and cysteine (C).
- cross-linkers include, but are not limited to, SMPH, Sulfo-MBS, Sulfo-EMCS, Sulfo-GMBS, Sulfo-SIAB, Sulfo-SMPB, Sulfo-SMCC, SVSB, and SIA.
- Chemical cross-linkers available on the market may also be employed.
- IgG-derived substances can also be used as a linker.
- IgG-derived substances include IgG1 to IgG4 comprising (i) full (hinge-CH 2 CH 3 ) (ii) half (hinge-CH 3 ) and (iii) short (12aa hinge only).
- IgG4-CH 3 Preferable example is IgG4-CH 3 .
- alphavirus is meant to refer to RNA-containing viruses that belong to the Togaviridae family of viruses.
- Exemplary Togaviridae viruses include but are not limited to Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus, Mucambo Virus, Pixuna Virus, Western Equine Encephalitis Virus (WEEV), Sindbis Virus, Semliki Forest Virus, Middleburg Virus, Chikungunya Virus (CHIKV), O'nyong-nyong Virus, Ross River Virus, Barmah Forest Virus, Getah Virus, Sagiyama Virus, Bebaru Virus, Mayaro Virus, Una Virus, Aura Virus, Whataroa Virus, Babanki Virus, Kyzylagach Virus, Highlands J virus, Fort Morgan Virus, Ndumu Virus, Buggy Creek Virus and Ockelbo virus.
- EEEV Eastern Equine Encephalitis
- alphavirus structural protein is meant a polypeptide or fragment thereof having at least about 80% amino acid sequence identity to a naturally occurring viral capsid or envelope protein.
- the alphavirus structural protein has at least about 85%, 90%, 95% or greater amino acid sequence identity with Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus, Mucambo Virus, Pixuna Virus, Western Equine Encephalitis Virus (WEEV), Sindbis Virus, Semliki Forest Virus, Middleburg Virus, Chikungunya Virus (CHIKV), O'nyong-nyong Virus, Ross River Virus, Barmah Forest Virus, Getah Virus, Sagiyama Virus, Bebaru Virus, Mayaro Virus, Una Virus, Aura Virus, Whataroa Virus, Babanki Virus, Kyzylagach Virus, Highlands J virus, Fort Morgan Virus, Ndumu Virus, or
- the alphavirus is a CHIKV, for example CHIKV strain 37997 or LR2006 OPY-1.
- the alphavirus is a VEEV, for example VEEV strain TC-83.
- an alphavirus replicon is meant an RNA molecule which can direct its own amplification in vivo in a target cell.
- the replicon encodes the polymerase(s) which catalyze RNA amplification (nspl, nsp2, nsp3, nsp4) and contains cis RNA sequences required for replication which are recognized and utilized by the encoded polymerase(s).
- An alphavirus replicon typically contains the following ordered elements: 5' UTR, sequences which encode alphavirus nonstructural proteins (nspl, nsp2, nsp3, nsp4), 3' UTR, and a poly A signal.
- An alphavirus replicon also contains one or more viral sub-genomic promoters directing the expression of the gene of interest. Those sequences may have one or more mutations taught in a prior art.
- the alphavirus replicon provided by the present disclosure may have the construct shown in Figure 1.
- fragment is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
- a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- reference is meant a standard or control condition.
- a “reference sequence” is a defined sequence used as a basis for sequence comparison.
- a reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
- the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids.
- the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or there between.
- Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e ⁇ "3> and e ⁇ "100> indicating a closely related sequence.
- sequence analysis software for example, Sequence Analysis Software Package of the Genetics Computer Group, University
- an effective amount is meant the amount of an agent required to ameliorate the symptoms of a disease relative to an untreated patient.
- the effective amount of active compound(s) used to practice the present invention for prevention or treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
- a satisfactory effect can be obtained by systemic administration, e.g. intramuscular administration, subcutaneous administration or intravenous administration 1-4 times at the amount of 10 3 -10 10 Infectious Unit (IU) or 0.01-500 ⁇ g per time, preferably 10 5 -10 10 IU or 0.1-100 ⁇ g per time, for example 10 7 -10 9 IU or 1-50 ⁇ g per one time.
- the replicon may preferably be formulated in a vaccine composition suitable for administration in a conventional manner.
- subject is meant a mammal, including, but not limited to, a human or non- human mammal, such as a bovine, equine, canine, ovine, or feline.
- treat refers to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- the terms "prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.
- Any vaccine compositions or methods provided herein can be combined with one or more of any of the other vaccine compositions and methods provided herein.
- vector refers to the means by which a nucleic acid sequence can be propagated and/or transferred between organisms, cells, or cellular components.
- Vectors include plasmids, viruses, bacteriophages, pro-viruses, phagemids, transposons, artificial chromosomes, and the like, that replicate autonomously or can integrate into a chromosome of a host cell.
- a vector can also be a naked RNA polynucleotide, a naked DNA polynucleotide, a polynucleotide composed of both DNA and RNA within the same strand, a poly-lysine-conjugated DNA or RNA, a peptide-conjugated DNA or RNA, a liposome-conjugated DNA, or the like, that is not autonomously replicating.
- the vectors of the present invention are plasmids or bacmids.
- the nucleic acid molecule to be expressed is "operably linked" to a promoter and/or enhancer, and is subject to transcription regulatory control by the promoter and/or enhancer.
- transfection and the choice of expression vehicle will depend on the host system selected. Transfection methods are described, e.g., in Ausubel et al. (supra); expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (P. H. Pouwels et al., 1985, Supp. 1987) The references cited in this paragraph are herein incorporated by reference.
- Expression vectors useful for producing the constructs include, without limitation, chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as alphavirus (e.g.
- Chikungunya Virus (CHIKV) and Venezuelan Equine Encephalitis Virus (VEEV)
- baculoviruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof.
- Constructs and/or vectors used herein comprise alphavirus polynucleotides encoding nonstructural proteins nsp1, nsp2, nsp3 and nsp4 and a gene of interest encoding a polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or a transmembrane domain as discussed above.
- Specific example of the construct or vector is that shown in Figure 1.
- the vector may be, for example, a phage, plasmid, viral, or retroviral vector.
- the constructs and/or vectors that comprise the nucleotides should be operatively linked to an appropriate promoter, such as the CMV promoter, phage lambda PL promoter, the E. coli lac, phoA and tac promoters, the SV40 early and late promoters, and promoters of retroviral LTRs are non-limiting examples. Other suitable promoters will be known to the skilled artisan depending on the host cell and/or the rate of expression desired.
- the expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome-binding site for translation.
- the coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.
- Vectors will preferably include at least one selectable marker.
- markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
- virus vectors such as baculovirus, poxvirus (e.g., vaccinia virus, avipox virus, canarypox virus, fowlpox virus, raccoonpox virus, swinepox virus, etc.), adenovirus (e.g., canine adenovirus), herpesvirus, and retrovirus.
- vectors for use in bacteria comprise vectors for use in bacteria, which comprise pQE70, pQE60 and pQE-9, pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5.
- preferred eukaryotic vectors are pFastBacl pWINEO, pSV2CAT, pOG44, pXTl and pSG, pSVK3, pBPV, pMSG, and pSVL.
- Other suitable vectors will be readily apparent to the skilled artisan.
- Recombinant constructs can be prepared and used to transfect, can express viral proteins, including those described herein, into eukaryotic cells and/or prokaryotic cells.
- the present disclosure provides host cells which comprise a vector (or vectors) that contain nucleic acids which encode alphavirus structural proteins, including capsid, E3, E2, 6K, and El or portions thereof, and a vector that comprises nucleic acids which encode alphavirus nsp1, nsp2, nsp3 and nsp4, and at least one of coronavirus gene of interest under conditions which allow the formation of alphavirus replicon particle.
- said vector is a recombinant baculovirus.
- said recombinant baculovirus is transfected into an insect cell.
- said cell is an insect cell.
- said insect cell is a Sf9 cell.
- E. coli pET expression system (Novagen, Inc., Madison, Wis).
- DNA encoding a polypeptide is inserted into a pET vector in an orientation designed to allow expression. Since the gene encoding such a polypeptide is under the control of the T7 regulatory signals, expression of the polypeptide is achieved by inducing the expression of T7 RNA polymerase in the host cell. This is typically achieved by using host strains that express T7 RNA polymerase in response to IPTG induction.
- a recombinant polypeptide is then isolated according to standard methods known in the art, for example, those described herein.
- the constructs are produced by growing host cells transfected by the vectors under conditions whereby the recombinant proteins are expressed and the alphavirus replicon is generated, and constructs containing alphavirus replicon being packaged with the particle of alphavirus structural proteins are formed.
- the invention comprises a method of producing a construct, that involves co-transfecting a vector comprising a polynucleotide encoding alphavirus non-structural protein nsp1, nsp2, nsp3 and nsp4, and at least one gene of interest encoding the polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or transmembrane domain, and at least one vector each encoding at least one alphavirus structural protein into suitable host cells and expressing said alphavirus structural protein under conditions that allow construct formation.
- the eukaryotic cell is selected from the group consisting of, yeast, insect, amphibian, avian or mammalian cells. The selection of the appropriate growth conditions is within the skill or a person with skill of one of ordinary skill in the art.
- Methods to grow cells that produce alphavirus replicon particles of the invention include, but are not limited to, batch, batch-fed, continuous and perfusion cell culture techniques.
- cells co-transfected with a vector encoding an alphavirus replicon and a vector comprising a polypeptide encoding capsid, and a vector comprising a polynucleotide encoding envelope proteins, such as those derived from a CHIKV or VEEV are grown in a bioreactor or fermentation chamber where cells propagate and express protein (e.g., recombinant proteins) for purification and isolation.
- protein e.g., recombinant proteins
- a bioreactor is a chamber used to culture cells in which environmental conditions such as temperature, atmosphere, agitation and/or pH can be monitored.
- the bioreactor is a stainless steel chamber.
- said bioreactor is a pre-sterilized plastic bag (e.g., Cellbag.RTM., Wave Biotech, Bridgewater, N.J., the contents of the cited document is herein incorporated by reference).
- said pre-sterilized plastic bags are about 10 L to 1000 L bags.
- an RNA molecule such as an alphavirus replicon may be generated by conventional procedures known to the art from a template DNA sequence.
- IVT In vitro transcription
- IVT methods permit template-directed synthesis of RNA molecules.
- IVT methods permit synthesis of large quantities of RNA transcript.
- IVT utilizes a DNA template comprising a promoter sequence upstream of a sequence of interest.
- the promoter sequence is most commonly of bacteriophage origin such as the T7, T3 or SP6 promoter sequence but many other promotor sequences can be tolerated including those designed de novo. Transcription of the DNA template is typically best achieved by using the RNA polymerase corresponding to the specific bacteriophage promoter sequence.
- RNA polymerases include, but are not limited to T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase, among others. IVT is generally initiated at a dsDNA but can proceed on a single strand. Kits for in vitro transcription such as T7 transcription kit (RiboMax TM Express Large Scale RNA production System, Promega (WI USA)).
- the term “pharmaceutically acceptable carrier” means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal, including any and all aqueous solvents (e.g., water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles, such as sodium chloride, and Ringer's dextrose), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oil, and injectable organic esters, such as ethyloleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, and inert gases), isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dye
- Encapsulating substances refers to a delivery vehicle where the polynucleotide or vector is packaged, such as a replicon particle (e.g. the alphavirus replicon particle described in US patent publication No. 2019-0185822, the contents of the document is incorporated by reference) and a lipid delivery system (e.g. liposome).
- a replicon particle e.g. the alphavirus replicon particle described in US patent publication No. 2019-0185822, the contents of the document is incorporated by reference
- a lipid delivery system e.g. liposome
- the vaccine compositions or formulations of the present disclosure comprise a lipid delivery system, e.g., a liposome, a lioplexes, a lipid nanoparticle, or any combination thereof.
- the polynucleotides such as an alpha virus replicon described herein can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. Liposomes, lipoplexes, or lipid nanoparticles can be used to improve the efficacy of the polynucleotides directed protein production as these formulations can increase cell transfection by the polynucleotide; and/or increase the translation of encoded protein.
- the liposomes, lipoplexes, or lipid nanoparticles can also be used to increase the stability of the polynucleotides.
- Liposomes are artificially-prepared vesicles that may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of pharmaceutical formulations. Liposomes can be of different sizes.
- a multilamellar vesicle (MLV) may be hundreds of nanometers in diameter, and may contain a series of concentric bilayers separated by narrow aqueous compartments.
- a small unicellular vesicle (SUV) may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) may be between 50 and 500 nm in diameter.
- Liposome design may include, but is not limited to, opsonins or ligands to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis.
- Liposomes may contain a low or a high pH value in order to improve the delivery of the pharmaceutical formulations.
- liposomes may depend on the pharmaceutical formulation entrapped and the liposomal ingredients, the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimal size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and scale up production of safe and efficient liposomal products, etc.
- the polynucleotides such as alpha virus replicon described herein may be encapsulated by the liposome and/or it may be contained in an aqueous core that may then be encapsulated by the liposome.
- the polynucleotides such as alpha virus replicon described herein can be formulated in a cationic oil-in-water emulsion where the emulsion particle comprises an oil core and a cationic lipid that can interact with the polynucleotide anchoring the molecule to the emulsion particle.
- the polynucleotides described herein can be formulated in a water-in-oil emulsion comprising a continuous hydrophobic phase in which the hydrophilic phase is dispersed.
- the polynucleotides such as alpha virus replicon described herein can be formulated in a lipid- polycation complex.
- the polycation can include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine and the cationic peptides.
- the polynucleotides such as alpha virus replicon described herein can be formulated in a lipid nanoparticle (LNP).
- LNP lipid nanoparticle
- Lipid nanoparticle formulations typically comprise one or more lipids.
- the lipid is a cationic or an ionizable lipid.
- lipid nanoparticle formulations further comprise other components, including a phospholipid, a structural lipid, a quaternary amine compound, and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.
- the amount of the cationic and ionizable lipids in the lipid composition ranges from about 0.01 mol% to about 99 mol%.
- LNPs contain a pH-sensitive ionizable cationic lipid that attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation. At physiological pH, LNPs are neutral, eliminating a mechanism of toxicity seen with permanently cationic molecules.
- pH-sensitive lipids are responsible for responding to the acidic environment of the endosome and triggering the disruption of the endosome and release of the nucleic acid into the cell.
- This replicon based vaccine technology is a unique platform technology for the vaccination as a RNA can self-amplify to produce the vaccine antigen and deliver into the cellular organ. Moreover, this replicon based vaccine technology overcomes the challenges commonly associated with DNA based vaccines, such as risk of genome integration or the high doses and devices needed for administration, e.g. electroporation, and expects the higher immunogenicity with minimum dose based on the self-replication system over the mRNA technology.
- novel antigenically- active proteins/polypeptides are also useful for producing antibodies for diagnosis and protecting against coronaviruses while minimizing the possibility of ADE.
- the proteins/polypeptides disclosed herein include minimum sequences encoding the coronavirus RBD fused to a signal sequence and/or to a transmembrane domain (TMD) sequence, intended to maximize immunogenicity and minimize ADE.
- TMD transmembrane domain
- construct 1-8 Each gene encoding shown below construct 1-8 was synthesized by Integrated DNA Technologies, Inc. (https://www.idtdna.com/pages).
- hIL-2 signal sequence MYRMQLLSCIALSLALVTNS (SEQ ID NO: 2) COVID19-RBD: VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 3) HA(flexible-TM-Cyt): GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMC SNGSLQCRICI (SEQ ID NO: 4) hIL-2:human Interleukin-2 HA(flexilble-TM-Cyt): polypeptide of Influenza virus
- TIR TLR4(TM-Toll/interleukin-1 receptor domain (TIR)) MYRMQLLSCIALSLALVTNSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS GS KTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSS
- hIL-2 signal sequence https://www.ncbi.nlm.nih.gov/protein/P60568 UniProtKB/Swiss-Prot: P60568.1
- COVID19-RBD https://www.ncbi.nlm.nih.gov/nuccore/NC_045512
- NCBI Reference Sequence NC_045512.2
- HA(flexible-TM-Cyt) https://www.ncbi.nlm.nih.gov/protein/P03452 UniProtKB/Swiss-Prot: P03452.2 Human IgG4 https://www.uniprot.org/uniprot/P01861 UniProtKB: P01861
- Construct A SS1-RBD1(330-521) (SEQ ID NO: 37)
- Construct B SS2-RBD1(330-521)-TM2 (SEQ ID NO: 38)
- Construct C SS1-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 39)
- Construct D SS1-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID NO: 40)
- Construct E SS1-RBD2(330-530)-GS-Linker-GS-TM1 (SEQ ID NO: 41)
- Construct F SS1-RBD2(330-530)-GS-Linker-GS-TM2 (SEQ ID NO: 42)
- Construct G SS2-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 43)
- Construct H SS2-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID
- Signal sequence SS1 COVID-19 signal sequence (1-15): MFVFLVLLPLVSSQC (SEQ ID NO: 14)
- SS2 hIL-2 signal sequence: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 15)
- SS3 COVID-19 signal sequence (1-13): MFVFLVLLPLVSS (SEQ ID NO: 16)
- RBD1 COVID-19 RBD amino acid position 330 and 521
- RBD2 COVID-19 RBD amino acid position 330 and 530
- RBD3 COVID-19 RBD amino acid position 327 and 531
- RBD1 PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP (SEQ ID NO: 17)
- RBD2 PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 18)
- RBD3 VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST (SEQ ID NO: 19)
- Transmembrane-Cytoplasm TM-Cyt
- TM1 Human CD80* (TM-Cyt): LLPSWAIT LISVNGIFVI CCLTYCFAPR CRERRRNERL RRESVRPV (SEQ ID NO: 21) * CD80: https://www.ncbi.nlm.nih.gov/protein/NP_005182
- TM2 HA(flexible-TM-Cyt): GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 22)
- TM3 COVID19 (JMD-TM): GKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO: 23)
- JMD juxtamembrane domain
- GKYEQYIKWPWYIWL SEQ ID NO: 24
- TM GFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
- Example 2 Each gene of Interest DNA prepared in Example 1 and 2 was cloned into the VEEV replicon vector under the control of the subgenomic (SG) promoter.
- the VEEV replicon plasmid encoding each fragment was created by insertion at AscI and SbfI restriction sites to obtain the full-length VEEV TC-83 replicon construct.
- One example of the full length VEEV TC-83 plasmid vector is shown in Figure 2.
- Nucleotide sequences of SG promoter, 5'UTR, 3’UTR and Poly A tail are as follows. RNA sequences were obtained by using those DNA sequences as template.
- SG promoter cctgaatggactacgacatagtctagtccgccaag (SEQ ID NO: 26)
- 5'UTR ataggcggcgcatgagagaagcccagaccaattacctacccaaa (SEQ ID NO: 27)
- 3’UTR gcgatcgcatacagcaattggcaagctgcttacatagaactcgcggcgattggcatgcccttaaaattttttttttttctttttccgaatcggatttttttttttccgaatcggatttttttttttccgaatcggattttttttttccgaatcgg
- VEEV TC-83 Replicon nsP1-4 amino acid sequence is as follows.
- amino acid sequence of nsp3 which is corresponding from 1330-1886 in SEQ ID NO: 30 was replaced with the sequence shown below.
- the underlined sequence was different from SEQ ID NO: 30.
- alphavirus replicon particles 10 ⁇ g of the full-length replicon plasmid prepared in Example 3, 1 ⁇ g of VEEV Env expression plasmid and 1 ⁇ g of VEEV Capsid NLS mutant (or 1 ⁇ g VEEV Capsid expression plasmid) was transfected into HEK293T cells. The supernatant was harvested 48-96 hours after transfection. The replicon particle was purified by using an ion exchange column. HET293T or Vero cells were infected with dilutions of the purified particle preparation to determine the infectious titer. The purified replicon particles are used for producing antigens for diagnosis and vaccination.
- ssRBD construct A hIL-2ssRBD-TM: construct 1 (mouse HA) ssRBD-linker-TM: construct C (TM1: mouse CD80, Linker: mouse IgG4-CH3)
- mice were immunized intramuscularly three times (on Day0, Day7 and Day14) with the indicated Replicon particles (RBD or RBD-linker-TM, 10 ⁇ 7IU/dose), a control Replicon particle or a DNA vaccine (20ug/dose), and sera were collected on Day14 (7days after 2nd immunization) and Day35 (21 days after 3nd immunization). These sera were examined in ELISA assays performed against a COVID-19-Spike S1 or RBD antigen. The symbols show the average of the five mice in each group, and error bars show the s.e.m. The curve fit was calculated by Prism software. These results are shown in Figure 4 (4-1 and 4-2) and Figure 5 (5-1 and 5-2).
- Figures 4 and 5 show that significantly higher titers of antibody against recombinant Coronavirus RBD and Spike S1 were achieved after immunization with replicon vaccines. In contrast, very low titers of antibody were induced with the DNA vaccine.
- mice were immunized intramuscularly with the indicated Replicon vaccines (CD80 or HA No.1, 10 ⁇ 5IU/dose) or PBS, and sera were collected 7 days after immunization. These sera were subject to ELISA analysis performed against a COVID-19-Spike S1 antigen. The symbols show the mean of the five mice in each group, and error bars show the s.e.m. These results are shown in Figure 6.
- Figure 6 shows that significantly higher titers of antibody against recombinant Coronavirus Spike S1 were achieved after immunization with replicon vaccines.
- RNA self-amplifying RNA
- LNP lipid nanoparticles
- saRNA(RBD-CD80TM) particles Lipid nanoparticles with no RNA was used as control.
- mice were bleed on Day 14, 28 and 46.
- the antibody titer against S1 protein in the sera from the immunized mice were measured by ELISA.
- the plate were coated with S1 protein (Sinobio 100ng/ml). Results are shown in Figure 6.
- the COVID-19 RBD may be derived from COVID-19 mutants.
- the following amino acid sequences of constructions comprising the COVID-19 signal sequence, COVID-19 RBD derived from a COVID-19 mutant, and human HA(flexible-TM-Cyt) are also used for generating alphavirus replicon as shown in Figure 1.
- the gene of interest is replaced with the polynucleotide encoding the following amino acid sequence.
- Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) is generated in the same manner as Example 8.
Abstract
Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
Description
The present disclosure relates generally to the field of a vaccine and to a method and a composition for treating and/or immunizing against viral infections. In particular, the present disclosure relates to a vaccine for coronavirus such as SARS-CoV-2 (COVID-19).
Coronaviruses are a large family of viruses that usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. However, three new coronaviruses have emerged from animal reservoirs over the past two decades to cause serious and widespread illness and death.
There are hundreds of coronaviruses, most of which circulate among such animals as pigs, camels, bats and cats. Sometimes those viruses jump to humans-called a spillover event-and can cause disease. Four of the seven known coronaviruses that sicken people cause only mild to moderate disease. Three can cause more serious, even fatal, disease. SARS coronavirus (SARS-CoV) emerged in November 2002 and caused severe acute respiratory syndrome (SARS). That virus disappeared by 2004. Middle East respiratory syndrome (MERS) is caused by the MERS coronavirus (MERS-CoV). Transmitted from an animal reservoir in camels, MERS was identified in September 2012 and continues to cause sporadic and localized outbreaks. The third novel coronavirus to emerge in this century is called SARS-CoV-2. It causes coronavirus disease 2019 (COVID-19), which emerged from China in December 2019 and was declared a global pandemic by the World Health Organization on March 11, 2020. (https://www.niaid.nih.gov/diseases-conditions/coronaviruses)
Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. At this time, there are no specific vaccines or treatments for COVID-19. (https://www.who.int/health-topics/coronavirus#tab=tab_1)
Because they are given to large numbers of healthy people, vaccines usually have a higher bar for safety than do drugs administered to people who are already ill. With SARS-CoV-2 (COVID-19) vaccines, researchers’ main safety concern is to avoid a phenomenon called disease enhancement, in which vaccinated people who do get infected develop a more severe form of the disease than people who have never been vaccinated. In studies of an experimental SARS vaccine reported in 2004, vaccinated ferrets developed damaging inflammation in their livers after being infected with the virus.
Antibody-dependent enhancement (ADE) is a mechanism by which some viruses such as dengue virus, feline coronavirus, and HIV, as an alternative strategy, can infect host cells that display Fc receptors and thereby take advantage of anti-viral humoral immune responses. Whether ADE occurs in SARS-Coronavirus infections is controversial, but it has been reported that antibodies against the spike protein of SARS-Coronavirus may cause ADE effect.
Peter Hotez, a vaccine scientist at Baylor College of Medicine in Houston, Texas, thinks potential vaccines should be tested in animals first to rule out disease enhancement, before trials move on to humans. He says he understands the reasoning for pushing SARS-CoV-2 (COVID-19) vaccines to human tests quickly, but adds that, because of the possibility that a vaccine could enhance disease, “I’m not sure this is the vaccine you want to do it for”. (Non-Patent Literature 1)
Thus, there is a need in the art for a safer vaccine for coronaviruses that could avoid the ADE effect.
[PL1]WO 2019/124441
[NPL 1]Nature 579, 481 (2020)
The present disclosure relates to novel antigenically-active proteins/polypeptides capable of inducing protection against coronaviruses while minimizing the possibility of ADE. T
he protein/polypeptide disclosed herein include a coronavirus structural protein fused to a signal sequence and/or a transmembrane domain. The coronavirus structural protein may be a spike(S) protein, nucleocapsid (N) protein, membrane (M) protein, a small envelope protein (E) or a combination thereof. Specific examples may include S1 and/or S2 subunit of the spike protein and especially, receptor binding domain of the S1 subunit.
he protein/polypeptide disclosed herein include a coronavirus structural protein fused to a signal sequence and/or a transmembrane domain. The coronavirus structural protein may be a spike(S) protein, nucleocapsid (N) protein, membrane (M) protein, a small envelope protein (E) or a combination thereof. Specific examples may include S1 and/or S2 subunit of the spike protein and especially, receptor binding domain of the S1 subunit.
In another aspect, the present disclosure relates to a novel polynucleotide encoding the above discussed novel antigenically-active proteins/polypeptides capable of inducing protection against coronaviruses.
In another aspect, the present disclosure relates to a novel alphavirus replicon that can express the above discussed antigenically-active protein/polypeptide. The alphavirus replicon includes polynucleotide such as RNA encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polynucleotide encoding the above-discussed antigenically active protein/polypeptide as a gene of interest.
In yet another aspect, the present disclosure relates to a vaccine comprising the above discussed polypeptide or polynucleotide. Especially, the present disclosure provides a vaccine comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, and a polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or transmembrane domain. The vaccine can be used for preventing and/or treating a subject from coronavirus infection.
In yet another aspect, the present disclosure relates to a method for immunizing, preventing or treating a subject from coronavirus infection comprising administering an effective amount of the above-discussed polypeptide or polypeptide to the subject in need thereof.
In still another aspect, the present disclosure relates to use of the above-discussed polypeptide or polynucleotide for the manufacture of a medicament.
As used herein “coronavirus” is meant to refer to single-stranded, positive-sense RNA viruses that belong to the family, Coronaviridae. Exemplary Coronaviridae viruses include but are not limited to SARS-Cov, MERS-Cov and SARS-CoV-2 (COVID-19). SARS-CoV-2 (COVID-19) may include known and unknown mutants. Known mutants may include COVID-19 E484K_N501Y_K417T mutant (Brazil Strain Mutant), E484K_N501Y_K417N mutant (South African Mutant) and E484K mutant. The coronavirus genome encodes numerous non-structural proteins and four major structural proteins including the spike (S), nucleocapsid (N), membrane (M) and small envelope (E). Spike (S) protein, a large envelope glycoprotein, is composed of S1 and S2 subunits. The “Receptor-binding domain (RBD)” is located in the S1 subunit. Preferable example of the structural protein used herein is coronavirus RBD. Spike protein, S1 and S2 subunits of the spike protein and RBD of COVID-19 and its mutants have been identified and published (Wrapp et al., Science 10.1126/science.abb2507(2020), Z. Wang et al., (preprint) bioRxiv 2021.01.15.426911; doi: https://doi.org/10.1101/2021.01.15.426911).
“Coronavirus structural protein” used herein may be a naturally occurring virus structural protein or a modified protein thereof. The modified protein may be a fragment of the naturally occurring virus structural protein. In one embodiment, the modified protein has at least 70%, 75%, 80%, 85%, 90%, 95% or 98% amino acid sequence identity to a naturally occurring viral structural protein or its fragment. In one embodiment, the modified protein is a mutant where at most 10% of the amino acids are deleted, substituted, and/or added based on a naturally occurring viral envelope protein or its fragment.
As used herein, “transmembrane domain (TM)” is a protein derived either from a natural or from a synthetic source. Where the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein. In one aspect, the membrane-bound or transmembrane protein is a protein heterologous to COVID-19. Examples of the membrane-bound or transmembrane proteins may include the alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154; toll-like receptors (TLR) such as TLR1-TLR10 in human and TLR1-TLR9, TLR11-TLR13 in mouse; interleukin (IL) receptors such as IL-1-28 receptor, RANTES receptors (CCR1, CCR3, CCR5), MIP-1 receptor, PF4 receptor, M-CSF receptor and NAP-2 receptor belonging to GPCR chemokine receptor; hemagglutinin (HA). In another aspect, the membrane-bound or transmembrane protein is a protein derived from COVID-19, such as COVID-19 spike protein.
Examples of transmembrane proteins may also include the followings:
5-Lipoxygenase-Activating Protein, ABC Transporters, ACBP, Amyloid beta (A4), Bcl-2 Inhibitors, BNIPs, CAAX protease, Cytochromes P450, E-NPPs, EPHA1, EPHA2, EPHA3, EPHA4, Fatty Acid Desaturases, Gamma secretase, Glucose transporter, Glycophorins, GPCR, HER2/ErbB2, HER3/ErbB3, HER4/ErbB4, HSD-11β, Hypoxia-induced Proteins, Immunoglobulins, Insulin receptor, Integrins, Ion channel, MAPEG, MFS, MinK Family, MPPs, Peptidase AD, Peptidase Family M48, Peptidase MA, Protein Jagged, Receptor-type Kinases, SNARE Complex, Sulfatases, TNF receptor, Transmembrane Proteins 14, Transporter, TROBP, VEGF receptors, Aldehyde Dehydrogenases, Ammonia and Urea transporters, FMN-linked Oxidoreductases, Leucine Rich Repeat (LRR)-Containing Transmembrane Proteins, Leukotriene C4 synthase, Lysosome-associated membrane glycoprotein, Major Intrinsic Protein (MIP)/FNT superfamily, Microsomal prostaglandin E synthase, N-(deoxy)ribosyltransferase-like Membrane Proteins, Neutral/alkaline Ceramidases, Oligosaccharyl Transferase, Pentameric Ligand-gated Ion Channels, Rhodopsin-like receptors and pumps, Single-helix ATPase Regulators, Squalene/ phytoene Synthase, Stearoyl -CoA desaturase 1, Stannin (SNN) Membrane Proteins, T-cell Surface Glycoprotein CD3 Zeta Chain, Tetratricopeptide repeat (TPR) Alpha-Helical Repeat Proteins, Transmembrane Proteins with NAD(P)-binding Rossmann-fold Domains.
5-Lipoxygenase-Activating Protein, ABC Transporters, ACBP, Amyloid beta (A4), Bcl-2 Inhibitors, BNIPs, CAAX protease, Cytochromes P450, E-NPPs, EPHA1, EPHA2, EPHA3, EPHA4, Fatty Acid Desaturases, Gamma secretase, Glucose transporter, Glycophorins, GPCR, HER2/ErbB2, HER3/ErbB3, HER4/ErbB4, HSD-11β, Hypoxia-induced Proteins, Immunoglobulins, Insulin receptor, Integrins, Ion channel, MAPEG, MFS, MinK Family, MPPs, Peptidase AD, Peptidase Family M48, Peptidase MA, Protein Jagged, Receptor-type Kinases, SNARE Complex, Sulfatases, TNF receptor, Transmembrane Proteins 14, Transporter, TROBP, VEGF receptors, Aldehyde Dehydrogenases, Ammonia and Urea transporters, FMN-linked Oxidoreductases, Leucine Rich Repeat (LRR)-Containing Transmembrane Proteins, Leukotriene C4 synthase, Lysosome-associated membrane glycoprotein, Major Intrinsic Protein (MIP)/FNT superfamily, Microsomal prostaglandin E synthase, N-(deoxy)ribosyltransferase-like Membrane Proteins, Neutral/alkaline Ceramidases, Oligosaccharyl Transferase, Pentameric Ligand-gated Ion Channels, Rhodopsin-like receptors and pumps, Single-helix ATPase Regulators, Squalene/ phytoene Synthase, Stearoyl -CoA desaturase 1, Stannin (SNN) Membrane Proteins, T-cell Surface Glycoprotein CD3 Zeta Chain, Tetratricopeptide repeat (TPR) Alpha-Helical Repeat Proteins, Transmembrane Proteins with NAD(P)-binding Rossmann-fold Domains.
In addition, monotypic/peripheral proteins that attached to the lipid bilayer or other integral proteins and peptide may also be used as transmembrane proteins. Examples may include Alpha/Beta-Hydrolase, Annexins, Bet V1-Like Protein, C1 Domain-Containing Protein, C2 Domain-containing Protein, CoA-Dependent Acyltransferases, CRAL-TRIO Domain-Containing Protein, DNase I-like protein, Fibrinogen , FYVE/PHD Zinc Finger Protein, Galactose-Binding Domain-Like Protein, Glycolipid Transfer Protein, Immunoglobulin-Like Superfamily (E Set) Protein, Lipocalin, Lipoxygenase, PGBD superfamily, PH Domain-Like Protein, Phosphatidylinositol 3-/4-Kinase, PLC-like Phosphodiesterase, Phosphotyrosine Protein Phosphatases II, P-Loop Containing Nucleoside Triphosphate Hydrolase, Protein kinase superfamily , PX Domain-Containing Protein, Saposin , Synuclein and Transcriptional factor tubby.
The expression "transmembrane domain" used in the present disclosure includes at least transmembrane region(s) of the membrane-bound or transmembrane protein. In addition, the transmembrane domain may also include juxtamembrane domain (JMD) and/or cytoplasmic tail of the membrane-bound or transmembrane protein.
Alternatively, the transmembrane domain in some embodiments is synthetic. In some aspects, the synthetic transmembrane domain comprises predominantly hydrophobic residues such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain.
Preferable transmembrane domain may be those derived from influenza virus hemagglutinin (HA), CD80, Toll-like receptor 4(TLR4) or COVID-19 spike protein. Specific examples may include a protein consisting of the flexible juxtamembrane region or flexible linker, the transmembrane domain and the cytoplasmic tail of Influenza virus hemagglutinin "HA (flexible-TM-Cyt)"; a protein consisting of transmembrane domain and cytoplasmic tail of human CD80; a protein consisting of transmembrane domain(TM) and Toll/interleukin-1 receptor domain (TIR), and a protein consisting of the juxtamembrane domain (JMD) and TM of COVID-19 Spike (S).
As used herein, "signal sequence" (sometimes referred to as signal peptide, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide) is a polynucleotide or polypeptide, depending on the context. Signal sequence is from about 9 to 200 nucleotides or 3-70 amino acids in length that, optionally, is incorporated at the 5' or N-terminus of the coding region or the protein. Some signal sequences are cleaved from the protein, for example by a signal peptidase after the proteins are transported to the desired site.
In some embodiments, the signal sequence of IL-2, especially human IL-2 may be employed. In another embodiments, the signal sequence of the COVID-19 spike protein may be employed.
The coronavirus structural protein, the transmembrane domain and/or the signal sequence may be directly or indirectly fused. In one embodiment, one or two linkers may intervene between them.
Also the coronavirus structural protein, the transmembrane domain and/or the signal sequence can be truncated and replaced by short linkers. In some embodiments, the coronavirus structural protein, the transmembrane domain and/or the signal sequence include one or more peptide linkers.
An example of a short linker consists of from 2 to 25 amino acids (e.g. 2, 3, 4, 5 or 6 amino acids). Usually, it is from 2 to 15 amino acids in length, such as SG, GS, SGG, GGS SGSG and TRGGS. In certain circumstances, the linker can consist of only one amino acid, such as glycine(G), serine (S) and cysteine (C).
When the coronavirus structural protein is chemically conjugated to the transmembrane domain and/or the signal sequence through a chemical cross-linker, examples of the cross-linkers include, but are not limited to, SMPH, Sulfo-MBS, Sulfo-EMCS, Sulfo-GMBS, Sulfo-SIAB, Sulfo-SMPB, Sulfo-SMCC, SVSB, and SIA. Chemical cross-linkers available on the market may also be employed.
IgG-derived substances can also be used as a linker. Examples of IgG-derived substances include IgG1 to IgG4 comprising (i) full (hinge-CH2CH3) (ii) half (hinge-CH3) and (iii) short (12aa hinge only). Preferable example is IgG4-CH3.
As used herein "alphavirus" is meant to refer to RNA-containing viruses that belong to the Togaviridae family of viruses. Exemplary Togaviridae viruses include but are not limited to Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus, Mucambo Virus, Pixuna Virus, Western Equine Encephalitis Virus (WEEV), Sindbis Virus, Semliki Forest Virus, Middleburg Virus, Chikungunya Virus (CHIKV), O'nyong-nyong Virus, Ross River Virus, Barmah Forest Virus, Getah Virus, Sagiyama Virus, Bebaru Virus, Mayaro Virus, Una Virus, Aura Virus, Whataroa Virus, Babanki Virus, Kyzylagach Virus, Highlands J virus, Fort Morgan Virus, Ndumu Virus, Buggy Creek Virus and Ockelbo virus.
By "alphavirus structural protein" is meant a polypeptide or fragment thereof having at least about 80% amino acid sequence identity to a naturally occurring viral capsid or envelope protein. In one embodiment, the alphavirus structural protein has at least about 85%, 90%, 95% or greater amino acid sequence identity with Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus, Mucambo Virus, Pixuna Virus, Western Equine Encephalitis Virus (WEEV), Sindbis Virus, Semliki Forest Virus, Middleburg Virus, Chikungunya Virus (CHIKV), O'nyong-nyong Virus, Ross River Virus, Barmah Forest Virus, Getah Virus, Sagiyama Virus, Bebaru Virus, Mayaro Virus, Una Virus, Aura Virus, Whataroa Virus, Babanki Virus, Kyzylagach Virus, Highlands J virus, Fort Morgan Virus, Ndumu Virus, or Buggy Creek Virus. Wild type amino acid sequences of alphavirus structural proteins can be obtained from GenBank.
In specific embodiments, the alphavirus is a CHIKV, for example CHIKV strain 37997 or LR2006 OPY-1. In other embodiments, the alphavirus is a VEEV, for example VEEV strain TC-83.
By "an alphavirus replicon" is meant an RNA molecule which can direct its own amplification in vivo in a target cell. The replicon encodes the polymerase(s) which catalyze RNA amplification (nspl, nsp2, nsp3, nsp4) and contains cis RNA sequences required for replication which are recognized and utilized by the encoded polymerase(s). An alphavirus replicon typically contains the following ordered elements: 5' UTR, sequences which encode alphavirus nonstructural proteins (nspl, nsp2, nsp3, nsp4), 3' UTR, and a poly A signal. An alphavirus replicon also contains one or more viral sub-genomic promoters directing the expression of the gene of interest. Those sequences may have one or more mutations taught in a prior art.
The alphavirus replicon provided by the present disclosure may have the construct shown in Figure 1.
In this disclosure, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean " includes," "including," and the like; "consisting essentially of or "consists essentially" likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
By "reference" is meant a standard or control condition.
A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or there between.
Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e<"3> and e<"100> indicating a closely related sequence.
By "effective amount" is meant the amount of an agent required to ameliorate the symptoms of a disease relative to an untreated patient. The effective amount of active compound(s) used to practice the present invention for prevention or treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
A satisfactory effect can be obtained by systemic administration, e.g. intramuscular administration, subcutaneous administration or intravenous administration 1-4 times at the amount of 103-1010 Infectious Unit (IU) or 0.01-500 μg per time, preferably 105-1010 IU or 0.1-100 μg per time, for example 107-109 IU or 1-50 μg per one time. The replicon may preferably be formulated in a vaccine composition suitable for administration in a conventional manner.
By "subject" is meant a mammal, including, but not limited to, a human or non- human mammal, such as a bovine, equine, canine, ovine, or feline.
As used herein, the terms "treat," treating," "treatment," and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
As used herein, the terms "prevent," "preventing," "prevention," "prophylactic treatment" and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.
Unless specifically stated or obvious from context, as used herein, the term "or" is understood to be inclusive.
Unless specifically stated or obvious from context, as used herein, the terms "a", "an", and "the" are understood to be singular or plural.
The art will acknowledge that polynucleotide sequences described in the specification and claims will recite "T"s in a representative DNA sequence but where the sequence represents RNA, the "T"s would be substituted for "U"s.
Any vaccine compositions or methods provided herein can be combined with one or more of any of the other vaccine compositions and methods provided herein.
The term "vector" refers to the means by which a nucleic acid sequence can be propagated and/or transferred between organisms, cells, or cellular components. Vectors include plasmids, viruses, bacteriophages, pro-viruses, phagemids, transposons, artificial chromosomes, and the like, that replicate autonomously or can integrate into a chromosome of a host cell. A vector can also be a naked RNA polynucleotide, a naked DNA polynucleotide, a polynucleotide composed of both DNA and RNA within the same strand, a poly-lysine-conjugated DNA or RNA, a peptide-conjugated DNA or RNA, a liposome-conjugated DNA, or the like, that is not autonomously replicating. In many, but not all, common embodiments, the vectors of the present invention are plasmids or bacmids.
Typically, the nucleic acid molecule to be expressed is "operably linked" to a promoter and/or enhancer, and is subject to transcription regulatory control by the promoter and/or enhancer.
The method of transfection and the choice of expression vehicle will depend on the host system selected. Transfection methods are described, e.g., in Ausubel et al. (supra); expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (P. H. Pouwels et al., 1985, Supp. 1987) The references cited in this paragraph are herein incorporated by reference.
A variety of expression systems exist for the production of the constructs of the invention. Expression vectors useful for producing the constructs include, without limitation, chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as alphavirus (e.g. Chikungunya Virus (CHIKV) and Venezuelan Equine Encephalitis Virus (VEEV)), baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof.
Constructs and/or vectors used herein comprise alphavirus polynucleotides encoding nonstructural proteins nsp1, nsp2, nsp3 and nsp4 and a gene of interest encoding a polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or a transmembrane domain as discussed above. Specific example of the construct or vector is that shown in Figure 1.
The vector may be, for example, a phage, plasmid, viral, or retroviral vector. The constructs and/or vectors that comprise the nucleotides should be operatively linked to an appropriate promoter, such as the CMV promoter, phage lambda PL promoter, the E. coli lac, phoA and tac promoters, the SV40 early and late promoters, and promoters of retroviral LTRs are non-limiting examples. Other suitable promoters will be known to the skilled artisan depending on the host cell and/or the rate of expression desired. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome-binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.
Vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Among vectors preferred are virus vectors, such as baculovirus, poxvirus (e.g., vaccinia virus, avipox virus, canarypox virus, fowlpox virus, raccoonpox virus, swinepox virus, etc.), adenovirus (e.g., canine adenovirus), herpesvirus, and retrovirus. Other vectors that can be used with the invention comprise vectors for use in bacteria, which comprise pQE70, pQE60 and pQE-9, pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5. Among preferred eukaryotic vectors are pFastBacl pWINEO, pSV2CAT, pOG44, pXTl and pSG, pSVK3, pBPV, pMSG, and pSVL. Other suitable vectors will be readily apparent to the skilled artisan.
Recombinant constructs can be prepared and used to transfect, can express viral proteins, including those described herein, into eukaryotic cells and/or prokaryotic cells. Thus, in one embodiment, the present disclosure provides host cells which comprise a vector (or vectors) that contain nucleic acids which encode alphavirus structural proteins, including capsid, E3, E2, 6K, and El or portions thereof, and a vector that comprises nucleic acids which encode alphavirus nsp1, nsp2, nsp3 and nsp4, and at least one of coronavirus gene of interest under conditions which allow the formation of alphavirus replicon particle.
In one embodiment, said vector is a recombinant baculovirus. In another embodiment, said recombinant baculovirus is transfected into an insect cell. In a preferred embodiment, said cell is an insect cell. In another embodiment, said insect cell is a Sf9 cell.
One particular bacterial expression system for polypeptide production is the E. coli pET expression system (Novagen, Inc., Madison, Wis). According to this expression system, DNA encoding a polypeptide is inserted into a pET vector in an orientation designed to allow expression. Since the gene encoding such a polypeptide is under the control of the T7 regulatory signals, expression of the polypeptide is achieved by inducing the expression of T7 RNA polymerase in the host cell. This is typically achieved by using host strains that express T7 RNA polymerase in response to IPTG induction. Once produced, a recombinant polypeptide is then isolated according to standard methods known in the art, for example, those described herein.
Depending on the vectors and host cells selected, the constructs are produced by growing host cells transfected by the vectors under conditions whereby the recombinant proteins are expressed and the alphavirus replicon is generated, and constructs containing alphavirus replicon being packaged with the particle of alphavirus structural proteins are formed. In one embodiment, the invention comprises a method of producing a construct, that involves co-transfecting a vector comprising a polynucleotide encoding alphavirus non-structural protein nsp1, nsp2, nsp3 and nsp4, and at least one gene of interest encoding the polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or transmembrane domain, and at least one vector each encoding at least one alphavirus structural protein into suitable host cells and expressing said alphavirus structural protein under conditions that allow construct formation. In another embodiment, the eukaryotic cell is selected from the group consisting of, yeast, insect, amphibian, avian or mammalian cells. The selection of the appropriate growth conditions is within the skill or a person with skill of one of ordinary skill in the art.
Methods to grow cells that produce alphavirus replicon particles of the invention include, but are not limited to, batch, batch-fed, continuous and perfusion cell culture techniques. In one embodiment, cells co-transfected with a vector encoding an alphavirus replicon and a vector comprising a polypeptide encoding capsid, and a vector comprising a polynucleotide encoding envelope proteins, such as those derived from a CHIKV or VEEV are grown in a bioreactor or fermentation chamber where cells propagate and express protein (e.g., recombinant proteins) for purification and isolation. Typically, cell culture is performed under sterile, controlled temperature and atmospheric conditions. A bioreactor is a chamber used to culture cells in which environmental conditions such as temperature, atmosphere, agitation and/or pH can be monitored. In one embodiment, the bioreactor is a stainless steel chamber. In another embodiment, said bioreactor is a pre-sterilized plastic bag (e.g., Cellbag.RTM., Wave Biotech, Bridgewater, N.J., the contents of the cited document is herein incorporated by reference). In other embodiment, said pre-sterilized plastic bags are about 10 L to 1000 L bags.
In another embodiment, an RNA molecule such as an alphavirus replicon may be generated by conventional procedures known to the art from a template DNA sequence. In vitro transcription (IVT) methods permit template-directed synthesis of RNA molecules. IVT methods permit synthesis of large quantities of RNA transcript. Generally, IVT utilizes a DNA template comprising a promoter sequence upstream of a sequence of interest. The promoter sequence is most commonly of bacteriophage origin such as the T7, T3 or SP6 promoter sequence but many other promotor sequences can be tolerated including those designed de novo. Transcription of the DNA template is typically best achieved by using the RNA polymerase corresponding to the specific bacteriophage promoter sequence. Exemplary RNA polymerases include, but are not limited to T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase, among others. IVT is generally initiated at a dsDNA but can proceed on a single strand. Kits for in vitro transcription such as T7 transcription kit (RiboMaxTM Express Large Scale RNA production System, Promega (WI USA)).
As used herein, the term “pharmaceutically acceptable carrier” means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal, including any and all aqueous solvents (e.g., water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles, such as sodium chloride, and Ringer's dextrose), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oil, and injectable organic esters, such as ethyloleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, and inert gases), isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, fluid and nutrient replenishers, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. The pH and exact concentration of the various components in a vaccine composition are adjusted according to well-known parameters.
Encapsulating substances refers to a delivery vehicle where the polynucleotide or vector is packaged, such as a replicon particle (e.g. the alphavirus replicon particle described in US patent publication No. 2019-0185822, the contents of the document is incorporated by reference) and a lipid delivery system (e.g. liposome).
In some embodiments, the vaccine compositions or formulations of the present disclosure comprise a lipid delivery system, e.g., a liposome, a lioplexes, a lipid nanoparticle, or any combination thereof. The polynucleotides such as an alpha virus replicon described herein can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. Liposomes, lipoplexes, or lipid nanoparticles can be used to improve the efficacy of the polynucleotides directed protein production as these formulations can increase cell transfection by the polynucleotide; and/or increase the translation of encoded protein. The liposomes, lipoplexes, or lipid nanoparticles can also be used to increase the stability of the polynucleotides.
Liposomes are artificially-prepared vesicles that may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of pharmaceutical formulations. Liposomes can be of different sizes. A multilamellar vesicle (MLV) may be hundreds of nanometers in diameter, and may contain a series of concentric bilayers separated by narrow aqueous compartments. A small unicellular vesicle (SUV) may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH value in order to improve the delivery of the pharmaceutical formulations.
The formation of liposomes may depend on the pharmaceutical formulation entrapped and the liposomal ingredients, the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimal size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and scale up production of safe and efficient liposomal products, etc.
In some embodiments, the polynucleotides such as alpha virus replicon described herein may be encapsulated by the liposome and/or it may be contained in an aqueous core that may then be encapsulated by the liposome.
In some embodiments, the polynucleotides such as alpha virus replicon described herein can be formulated in a cationic oil-in-water emulsion where the emulsion particle comprises an oil core and a cationic lipid that can interact with the polynucleotide anchoring the molecule to the emulsion particle. In some embodiments, the polynucleotides described herein can be formulated in a water-in-oil emulsion comprising a continuous hydrophobic phase in which the hydrophilic phase is dispersed.
In some embodiments, the polynucleotides such as alpha virus replicon described herein can be formulated in a lipid- polycation complex. As a non-limiting example, the polycation can include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine and the cationic peptides.
In some embodiments, the polynucleotides such as alpha virus replicon described herein can be formulated in a lipid nanoparticle (LNP).
Lipid nanoparticle formulations typically comprise one or more lipids. In some embodiments, the lipid is a cationic or an ionizable lipid. In some embodiments, lipid nanoparticle formulations further comprise other components, including a phospholipid, a structural lipid, a quaternary amine compound, and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid. In some embodiments, the amount of the cationic and ionizable lipids in the lipid composition ranges from about 0.01 mol% to about 99 mol%.
LNPs contain a pH-sensitive ionizable cationic lipid that attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation. At physiological pH, LNPs are neutral, eliminating a mechanism of toxicity seen with permanently cationic molecules.
These same pH-sensitive lipids are responsible for responding to the acidic environment of the endosome and triggering the disruption of the endosome and release of the nucleic acid into the cell.
This replicon based vaccine technology is a unique platform technology for the vaccination as a RNA can self-amplify to produce the vaccine antigen and deliver into the cellular organ. Moreover, this replicon based vaccine technology overcomes the challenges commonly associated with DNA based vaccines, such as risk of genome integration or the high doses and devices needed for administration, e.g. electroporation, and expects the higher immunogenicity with minimum dose based on the self-replication system over the mRNA technology.
According to the present invention, novel antigenically- active proteins/polypeptides are also useful for producing antibodies for diagnosis and protecting against coronaviruses while minimizing the possibility of ADE. The proteins/polypeptides disclosed herein include minimum sequences encoding the coronavirus RBD fused to a signal sequence and/or to a transmembrane domain (TMD) sequence, intended to maximize immunogenicity and minimize ADE.
The invention will be described in detail with reference to the following examples, which, however, are not intended to limit the scope of the present application.
Each gene encoding shown below construct 1-8 was synthesized by Integrated DNA Technologies, Inc. (https://www.idtdna.com/pages).
1. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and HA (flexible domain-Transmembrane(TM)-Cytoplasmic Tail(Cyt))
MYRMQLLSCIALSLALVTNSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 1)
hIL-2 signal sequence: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 2)
COVID19-RBD: VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 3)
HA(flexible-TM-Cyt): GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMC SNGSLQCRICI (SEQ ID NO: 4)
hIL-2:human Interleukin-2
HA(flexilble-TM-Cyt): polypeptide of Influenza virus
COVID19-RBD: VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 3)
HA(flexible-TM-Cyt): GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMC SNGSLQCRICI (SEQ ID NO: 4)
hIL-2:human Interleukin-2
HA(flexilble-TM-Cyt): polypeptide of Influenza virus
2. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and HA (flexible-TM-Cyt)
MYRMQLLSCIALSLALVTNSCVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSCGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 5)
“C” in the schematic chart: linker (Cysteine)
Linkers in the amino acid sequence are underlined.
“C” in the schematic chart: linker (Cysteine)
Linkers in the amino acid sequence are underlined.
3. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and HA (flexible-TM-Cyt) with linker
MYRMQLLSCIALSLALVTNSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSGSGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 6)
“GS” in the schematic chart: linker (GGATCC)
linkers are underlined in the amino acid sequence
human IgG4 CH3: GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 7)
“GS” in the schematic chart: linker (GGATCC)
linkers are underlined in the amino acid sequence
human IgG4 CH3: GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 7)
4. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and HA (Flexible-TM-Cyt) with linker
MYRMQLLSCIALSLALVTNSCVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSCGSGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 8)
“C” "CGS" and "GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
“C” "CGS" and "GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
5. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and human TLR4(TM-Toll/interleukin-1 receptor domain (TIR))
MYRMQLLSCIALSLALVTNSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSGSKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 9)
human TLR4(TM-TIR): KTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 10)
human TLR4(TM-TIR): KTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 10)
6. Construct of COVID-19-RBD gene sequence fused to hIL-2 signal sequence and human TLR4(TM-TIR)
MYRMQLLSCIALSLALVTNSCVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSCGSKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 11)
"C" and "CGS" in the schematic chart: linkers
Linkers are underlined in the amino acid sequence.
"C" and "CGS" in the schematic chart: linkers
Linkers are underlined in the amino acid sequence.
7. Construct of COVID-19-RBD sequence fused to hIL-2 signal sequence and human TLR4(TM-TIR) with linker
MYRMQLLSCIALSLALVTNSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSGSGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 12)
"GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
"GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
8. Construct of COVID19 RBD sequence fused to hIL-2 signal sequence and human TLR4(TM-TIR) with linker
MYRMQLLSCIALSLALVTNSCVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSCGSGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI (SEQ ID NO: 13)
"C, "CGS" and "GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
"C, "CGS" and "GS" in the schematic chart: linker
Linkers are underlined in the amino acid sequence.
Information regarding hIL-2 signal sequence, COVID19-RBD, human IgG4 CH3 and HA(flexible-TM-Cyt) are also available from the National Center for Biotechnology Information website and from UniProt website.
hIL-2 signal sequence
https://www.ncbi.nlm.nih.gov/protein/P60568
UniProtKB/Swiss-Prot: P60568.1
COVID19-RBD
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512
NCBI Reference Sequence: NC_045512.2
HA(flexible-TM-Cyt)
https://www.ncbi.nlm.nih.gov/protein/P03452
UniProtKB/Swiss-Prot: P03452.2
Human IgG4
https://www.uniprot.org/uniprot/P01861
UniProtKB: P01861
hIL-2 signal sequence
https://www.ncbi.nlm.nih.gov/protein/P60568
UniProtKB/Swiss-Prot: P60568.1
COVID19-RBD
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512
NCBI Reference Sequence: NC_045512.2
HA(flexible-TM-Cyt)
https://www.ncbi.nlm.nih.gov/protein/P03452
UniProtKB/Swiss-Prot: P03452.2
Human IgG4
https://www.uniprot.org/uniprot/P01861
UniProtKB: P01861
Each gene encoding shown below construct A-O was synthesized by Integrated DNA Technologies, Inc. (https://www.idtdna.com/pages).
Construct A: SS1-RBD1(330-521) (SEQ ID NO: 37)
Construct B: SS2-RBD1(330-521)-TM2 (SEQ ID NO: 38)
Construct C: SS1-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 39)
Construct D: SS1-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID NO: 40)
Construct E: SS1-RBD2(330-530)-GS-Linker-GS-TM1 (SEQ ID NO: 41)
Construct F: SS1-RBD2(330-530)-GS-Linker-GS-TM2 (SEQ ID NO: 42)
Construct G: SS2-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 43)
Construct H: SS2-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID NO: 44)
Construct I: SS2-RBD2(330-530)-GS-Linker-GS-TM1 (SEQ ID NO: 45)
Construct J: SS2-RBD2(330-530)-GS-Linker-GS-TM2 (SEQ ID NO: 46)
Construct K: SS3-RBD3(327-531)-TM2 (SEQ ID NO: 47)
Construct L: SS1-RBD2(330-521)-TM2 (SEQ ID NO: 48)
Construct M: SS1-RBD3(327-531)-C-TM3 (SEQ ID NO: 49)
Construct N: SS3-RBD3(327-531)-TM3 (SEQ ID NO: 50)
Construct O: SS3-RBD1(330-521)-TM3 (SEQ ID NO: 51)
Construct B: SS2-RBD1(330-521)-TM2 (SEQ ID NO: 38)
Construct C: SS1-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 39)
Construct D: SS1-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID NO: 40)
Construct E: SS1-RBD2(330-530)-GS-Linker-GS-TM1 (SEQ ID NO: 41)
Construct F: SS1-RBD2(330-530)-GS-Linker-GS-TM2 (SEQ ID NO: 42)
Construct G: SS2-RBD1(330-521)-GS-Linker-GS-TM1 (SEQ ID NO: 43)
Construct H: SS2-RBD1(330-521)-GS-Linker-GS-TM2 (SEQ ID NO: 44)
Construct I: SS2-RBD2(330-530)-GS-Linker-GS-TM1 (SEQ ID NO: 45)
Construct J: SS2-RBD2(330-530)-GS-Linker-GS-TM2 (SEQ ID NO: 46)
Construct K: SS3-RBD3(327-531)-TM2 (SEQ ID NO: 47)
Construct L: SS1-RBD2(330-521)-TM2 (SEQ ID NO: 48)
Construct M: SS1-RBD3(327-531)-C-TM3 (SEQ ID NO: 49)
Construct N: SS3-RBD3(327-531)-TM3 (SEQ ID NO: 50)
Construct O: SS3-RBD1(330-521)-TM3 (SEQ ID NO: 51)
Signal sequence
SS1: COVID-19 signal sequence (1-15): MFVFLVLLPLVSSQC (SEQ ID NO: 14)
SS2: hIL-2 signal sequence: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 15)
SS3: COVID-19 signal sequence (1-13): MFVFLVLLPLVSS (SEQ ID NO: 16)
SS1: COVID-19 signal sequence (1-15): MFVFLVLLPLVSSQC (SEQ ID NO: 14)
SS2: hIL-2 signal sequence: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 15)
SS3: COVID-19 signal sequence (1-13): MFVFLVLLPLVSS (SEQ ID NO: 16)
COVID-19-RBDs
RBD1: COVID-19 RBD amino acid position 330 and 521
RBD2: COVID-19 RBD amino acid position 330 and 530
RBD3: COVID-19 RBD amino acid position 327 and 531
RBD1: COVID-19 RBD amino acid position 330 and 521
RBD2: COVID-19 RBD amino acid position 330 and 530
RBD3: COVID-19 RBD amino acid position 327 and 531
RBD1: PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP (SEQ ID NO: 17)
RBD2:
PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 18)
PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS (SEQ ID NO: 18)
RBD3:
VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST (SEQ ID NO: 19)
VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST (SEQ ID NO: 19)
Linker
Human IgG4-CH3
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20)
Human IgG4-CH3
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20)
Transmembrane-Cytoplasm (TM-Cyt)
TM1: Human CD80* (TM-Cyt):
LLPSWAIT LISVNGIFVI CCLTYCFAPR CRERRRNERL RRESVRPV (SEQ ID NO: 21) * CD80: https://www.ncbi.nlm.nih.gov/protein/NP_005182
TM2: HA(flexible-TM-Cyt):
GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 22)
TM3: COVID19 (JMD-TM):
GKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO: 23)
TM1: Human CD80* (TM-Cyt):
LLPSWAIT LISVNGIFVI CCLTYCFAPR CRERRRNERL RRESVRPV (SEQ ID NO: 21) * CD80: https://www.ncbi.nlm.nih.gov/protein/NP_005182
TM2: HA(flexible-TM-Cyt):
GVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 22)
TM3: COVID19 (JMD-TM):
GKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO: 23)
The juxtamembrane domain (JMD) of spike protein is an aromatic amino acid-rich region proximal to the transmembrane domain that is highly conserved in all coronaviruses (Howard et al., JOURNAL OF VIROLOGY, Mar. 2008, p. 2883-2894 Vol. 82, No. 6, the contents of the reference is herein incorporated by reference).
JMD: GKYEQYIKWPWYIWL (SEQ ID NO: 24)
TM: GFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO: 25)
JMD: GKYEQYIKWPWYIWL (SEQ ID NO: 24)
TM: GFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO: 25)
Preparation of replicon vector. Schematic construct of the alphavirus replicon is shown in Figure 1.
Each gene of Interest DNA prepared in Example 1 and 2 was cloned into the VEEV replicon vector under the control of the subgenomic (SG) promoter. The VEEV replicon plasmid encoding each fragment was created by insertion at AscI and SbfI restriction sites to obtain the full-length VEEV TC-83 replicon construct. One example of the full length VEEV TC-83 plasmid vector is shown in Figure 2.
Nucleotide sequences of SG promoter, 5'UTR, 3’UTR and Poly A tail are as follows. RNA sequences were obtained by using those DNA sequences as template.
SG promoter: cctgaatggactacgacatagtctagtccgccaag (SEQ ID NO: 26)
5'UTR: ataggcggcgcatgagagaagcccagaccaattacctacccaaa (SEQ ID NO: 27)
3’UTR: gcgatcgcatacagcagcaattggcaagctgcttacatagaactcgcggcgattggcatgccgccttaaaatttttattttatttttcttttcttttccgaatcggattttgtttttaatatttc (SEQ ID NO: 28)
Poly A tail: aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa (SEQ ID NO: 29)
SG promoter: cctgaatggactacgacatagtctagtccgccaag (SEQ ID NO: 26)
5'UTR: ataggcggcgcatgagagaagcccagaccaattacctacccaaa (SEQ ID NO: 27)
3’UTR: gcgatcgcatacagcagcaattggcaagctgcttacatagaactcgcggcgattggcatgccgccttaaaatttttattttatttttcttttcttttccgaatcggattttgtttttaatatttc (SEQ ID NO: 28)
Poly A tail: aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa (SEQ ID NO: 29)
VEEV TC-83 Replicon nsP1-4 amino acid sequence is as follows.
MEKVHVDIEEDSPFLRALQRSFPQFEVEAKQVTDNDHANARAFSHLASKLIETEVDPSDTILDIGSAPARRMYSKHKYHCICPMRCAEDPDRLYKYATKLKKNCKEITDKELDKKMKELAAVMSDPDLETETMCLHDDESCRYEGQVAVYQDVYAVDGPTSLYHQANKGVRVAYWIGFDTTPFMFKNLAGAYPSYSTNWADETVLTARNIGLCSSDVMERSRRGMSILRKKYLKPSNNVLFSVGSTIYHEKRDLLRSWHLPSVFHLRGKQNYTCRCETIVSCDGYVVKRIAISPGLYGKPSGYAATMHREGFLCCKVTDTLNGERVSFPVCTYVPATLCDQMTGILATDVSADDAQKLLVGLNQRIVVNGRTQRNTNTMKNYLLPVVAQAFARWAKEYKEDQEDERPLGLRDRQLVMGCCWAFRRHKITSIYKRPDTQTIIKVNSDFHSFVLPRIGSNTLEIGLRTRIRKMLEEHKEPSPLITAEDIQEAKCAADEAKEVREAEELRAALPPLAADFEEPTLEADVDLMLQEAGAGSVETPRGLIKVTSYAGEDKIGSYAVLSPQAVLKSEKLSCIHPLAEQVIVITHSGRKGRYAVEPYHGKVVVPEGHAIPVQDFQALSESATIVYNEREFVNRYLHHIATHGGALNTDEEYYKTVKPSEHDGEYLYDIDRKQCVKKELVTGLGLTGELVDPPFHEFAYESLRTRPAAPYQVPTIGVYGVPGSGKSGIIKSAVTKKDLVVSAKKENCAEIIRDVKKMKGLDVNARTVDSVLLNGCKHPVETLYIDEAFACHAGTLRALIAIIRPKKAVLCGDPKQCGFFNMMCLKVHFNHEICTQVFHKSISRRCTKSVTSVVSTLFYDKRMRTTNPKETKIVIDTTGSTKPKQDDLILTCFRGWVKQLQIDYKGNEIMTAAASQGLTRKGVYAVRYKVNENPLYAPTSEHVNVLLTRTEDRIVWKTLAGDPWIKILTAKYPGNFTATIEEWQAEHDAIMRHILERPDPTDVFQNKANVCWAKALVPVLKTAGIDMTTEQWNTVDYFETDKAHSAEIVLNQLCVRFFGLDLDSGLFSAPTVPLSIRNNHWDNSPSPNMYGLNKEVVRQLSRRYPQLPRAVATGRVYDMNTGTLRNYDPRINLVPVNRRLPHALVLHHNEHPQSDFSSFVSKLKGRTVLVVGEKLSVPGKKVDWLSDQPEATFRARLDLGIPGDVPKYDIVFINVRTPYKYHHYQQCEDHAIKLSMLTKKACLHLNPGGTCVSIGYGYADRASESIIGAIARQFKFSRVCKPKSSHEETEVLFVFIGYDRKARTHNPYKLSSTLTNIYTGSRLHEAGCAPSYHVVRGDIATATEGVIINAANSKGQPGGGVCGALYKKFPESFDLQPIEVGKARLVKGAAKHIIHAVGPNFNKVSEVEGDKQLAEAYESIAKIVNDNNYKSVAIPLLSTGIFSGNKDRLTQSLNHLLTALDTTDADVAIYCRDKKWEMTLKEAVARREAVEEICISDDSSVTEPDAELVRVHPKSSLAGRKGYSTSDGKTFSYLEGTKFHQAAKDIAEINAMWPVATEANEQVCMYILGESMSSIRSKCPVEESEASTPPSTLPCLCIHAMTPERVQRLKASRPEQITVCSSFPLPKYRITGVQKIQCSQPILFSPKVPAYIHPRKYLVETPPVEETPESPAENQSTEGTPEQPALVNVDATRTRMPEPIIIEEEEEDSISLLSDGPTHQVLQVEADIHGSPSVSSSSWSIPHASDFDVDSLSILDTLDGASVTSGAVSAETNSYFARSMEFRARPVPAPRTVFRNPPHPAPRTRTPPLAHSRASSRTSLVSTPPGVNRVITREELEALTPSRAPSRSASRTSLVSNPPGVNRVITREEFEAFVAQQQXRFDAGAYIFSSDTGQGHLQQKSVRQTVLSEVVLERTELEISYAPRLDQEKEELLRKKLQLNPTPANRSRYQSRRVENMKAITARRILQGLGHYLKAEGKVECYRTLHPVPLYSSSVNRAFSSPKVAVEACNAMLKENFPTVASYCIIPEYDAYLDMVDGASCCLDTASFCPAKLRSFPKKHSYLEPTIRSAVPSAIQNTLQNVLAAATKRNCNVTQMRELPVLDSAAFNVECFKKYACNNEYWETFKENPIRLTEENVVNYITKLKGPKAAALFAKTHNLNMLQDIPMDRFVMDLKRDVKVTPGTKHTEERPKVQVIQAADPLATADLCGIHRELVRRLNAVLLPNIHTLFDMSAEDFDAIIAEHFQPGDCVLETDIASFDKSEDDAMALTALMILEDLGVDAELLTLIEAAFGEISSIHLPTKTKFKFGAMMKSGMFLTLFVNTVINIVIASRVLRERLTGSPCAAFIGDDNIVKGVKSDKLMADRCATWLNMEVKIIDAVVGEKAPYFCGGFILCDSVTGTACRVADPLKRLFKLGKPLAVDDEHDDDRRRALHEESTRWNRVGILPELCKAVESRYETVGTSIIVMAMTTLASSVKSFSYLRGAPITLYG (SEQ ID NO: 30)
Amino acid sequence corresponding to nsp3 is underlined.
MEKVHVDIEEDSPFLRALQRSFPQFEVEAKQVTDNDHANARAFSHLASKLIETEVDPSDTILDIGSAPARRMYSKHKYHCICPMRCAEDPDRLYKYATKLKKNCKEITDKELDKKMKELAAVMSDPDLETETMCLHDDESCRYEGQVAVYQDVYAVDGPTSLYHQANKGVRVAYWIGFDTTPFMFKNLAGAYPSYSTNWADETVLTARNIGLCSSDVMERSRRGMSILRKKYLKPSNNVLFSVGSTIYHEKRDLLRSWHLPSVFHLRGKQNYTCRCETIVSCDGYVVKRIAISPGLYGKPSGYAATMHREGFLCCKVTDTLNGERVSFPVCTYVPATLCDQMTGILATDVSADDAQKLLVGLNQRIVVNGRTQRNTNTMKNYLLPVVAQAFARWAKEYKEDQEDERPLGLRDRQLVMGCCWAFRRHKITSIYKRPDTQTIIKVNSDFHSFVLPRIGSNTLEIGLRTRIRKMLEEHKEPSPLITAEDIQEAKCAADEAKEVREAEELRAALPPLAADFEEPTLEADVDLMLQEAGAGSVETPRGLIKVTSYAGEDKIGSYAVLSPQAVLKSEKLSCIHPLAEQVIVITHSGRKGRYAVEPYHGKVVVPEGHAIPVQDFQALSESATIVYNEREFVNRYLHHIATHGGALNTDEEYYKTVKPSEHDGEYLYDIDRKQCVKKELVTGLGLTGELVDPPFHEFAYESLRTRPAAPYQVPTIGVYGVPGSGKSGIIKSAVTKKDLVVSAKKENCAEIIRDVKKMKGLDVNARTVDSVLLNGCKHPVETLYIDEAFACHAGTLRALIAIIRPKKAVLCGDPKQCGFFNMMCLKVHFNHEICTQVFHKSISRRCTKSVTSVVSTLFYDKRMRTTNPKETKIVIDTTGSTKPKQDDLILTCFRGWVKQLQIDYKGNEIMTAAASQGLTRKGVYAVRYKVNENPLYAPTSEHVNVLLTRTEDRIVWKTLAGDPWIKILTAKYPGNFTATIEEWQAEHDAIMRHILERPDPTDVFQNKANVCWAKALVPVLKTAGIDMTTEQWNTVDYFETDKAHSAEIVLNQLCVRFFGLDLDSGLFSAPTVPLSIRNNHWDNSPSPNMYGLNKEVVRQLSRRYPQLPRAVATGRVYDMNTGTLRNYDPRINLVPVNRRLPHALVLHHNEHPQSDFSSFVSKLKGRTVLVVGEKLSVPGKKVDWLSDQPEATFRARLDLGIPGDVPKYDIVFINVRTPYKYHHYQQCEDHAIKLSMLTKKACLHLNPGGTCVSIGYGYADRASESIIGAIARQFKFSRVCKPKSSHEETEVLFVFIGYDRKARTHNPYKLSSTLTNIYTGSRLHEAGCAPSYHVVRGDIATATEGVIINAANSKGQPGGGVCGALYKKFPESFDLQPIEVGKARLVKGAAKHIIHAVGPNFNKVSEVEGDKQLAEAYESIAKIVNDNNYKSVAIPLLSTGIFSGNKDRLTQSLNHLLTALDTTDADVAIYCRDKKWEMTLKEAVARREAVEEICISDDSSVTEPDAELVRVHPKSSLAGRKGYSTSDGKTFSYLEGTKFHQAAKDIAEINAMWPVATEANEQVCMYILGESMSSIRSKCPVEESEASTPPSTLPCLCIHAMTPERVQRLKASRPEQITVCSSFPLPKYRITGVQKIQCSQPILFSPKVPAYIHPRKYLVETPPVEETPESPAENQSTEGTPEQPALVNVDATRTRMPEPIIIEEEEEDSISLLSDGPTHQVLQVEADIHGSPSVSSSSWSIPHASDFDVDSLSILDTLDGASVTSGAVSAETNSYFARSMEFRARPVPAPRTVFRNPPHPAPRTRTPPLAHSRASSRTSLVSTPPGVNRVITREELEALTPSRAPSRSASRTSLVSNPPGVNRVITREEFEAFVAQQQXRFDAGAYIFSSDTGQGHLQQKSVRQTVLSEVVLERTELEISYAPRLDQEKEELLRKKLQLNPTPANRSRYQSRRVENMKAITARRILQGLGHYLKAEGKVECYRTLHPVPLYSSSVNRAFSSPKVAVEACNAMLKENFPTVASYCIIPEYDAYLDMVDGASCCLDTASFCPAKLRSFPKKHSYLEPTIRSAVPSAIQNTLQNVLAAATKRNCNVTQMRELPVLDSAAFNVECFKKYACNNEYWETFKENPIRLTEENVVNYITKLKGPKAAALFAKTHNLNMLQDIPMDRFVMDLKRDVKVTPGTKHTEERPKVQVIQAADPLATADLCGIHRELVRRLNAVLLPNIHTLFDMSAEDFDAIIAEHFQPGDCVLETDIASFDKSEDDAMALTALMILEDLGVDAELLTLIEAAFGEISSIHLPTKTKFKFGAMMKSGMFLTLFVNTVINIVIASRVLRERLTGSPCAAFIGDDNIVKGVKSDKLMADRCATWLNMEVKIIDAVVGEKAPYFCGGFILCDSVTGTACRVADPLKRLFKLGKPLAVDDEHDDDRRRALHEESTRWNRVGILPELCKAVESRYETVGTSIIVMAMTTLASSVKSFSYLRGAPITLYG (SEQ ID NO: 30)
Amino acid sequence corresponding to nsp3 is underlined.
In this example, amino acid sequence of nsp3 which is corresponding from 1330-1886 in SEQ ID NO: 30 was replaced with the sequence shown below. The underlined sequence was different from SEQ ID NO: 30.
APSYHVVRGDIATATEGVIINAANSKGQPGGGVCGALYKKFPESFDLQPIEVGKARLVKGAAKHIIHAVGPNFNKVSEVEGDKQLAEAYESIAKIVNDNNYKSVAIPLLSTGIFSGNKDRLTQSLNHLLTALDTTDADVAIYCRDKKWEMTLKEAVARREAVEEICISDDSSVTEPDAELVRVHPKSSLAGRKGYSTSDGKTFSYLEGTKFHQAAKDIAEINAMWPVATEANEQVCMYILGKSMSSIRSKCPVEESEASTPPSTLPCLCIHAMTPERVQRLKASRPEQITVCSSFPLPKYRITGVQKIQCSQPILFSPKVPAYIHPRKYLVETPPVDETPEPSAENQSTEGTPEQPPLITEDETRTRTPEPIIIEEEEEDSISLLSDGPTHQVLQVEADIHGPPSVSSSSWSIPHASDFDVDSLSILDTLEGASVTSGATSAETNSYFAKSMEFLARPVPAPRTVFRNPPHPAPRTRTPSLAPSRACSRTSLVSTPPGVNRVITREELEALTPSRTPSRSVSRTSLVSNPPGVNRVITREEFEAFVAQQQXRFDAGA (SEQ ID NO: 31)
APSYHVVRGDIATATEGVIINAANSKGQPGGGVCGALYKKFPESFDLQPIEVGKARLVKGAAKHIIHAVGPNFNKVSEVEGDKQLAEAYESIAKIVNDNNYKSVAIPLLSTGIFSGNKDRLTQSLNHLLTALDTTDADVAIYCRDKKWEMTLKEAVARREAVEEICISDDSSVTEPDAELVRVHPKSSLAGRKGYSTSDGKTFSYLEGTKFHQAAKDIAEINAMWPVATEANEQVCMYILGKSMSSIRSKCPVEESEASTPPSTLPCLCIHAMTPERVQRLKASRPEQITVCSSFPLPKYRITGVQKIQCSQPILFSPKVPAYIHPRKYLVETPPVDETPEPSAENQSTEGTPEQPPLITEDETRTRTPEPIIIEEEEEDSISLLSDGPTHQVLQVEADIHGPPSVSSSSWSIPHASDFDVDSLSILDTLEGASVTSGATSAETNSYFAKSMEFLARPVPAPRTVFRNPPHPAPRTRTPSLAPSRACSRTSLVSTPPGVNRVITREELEALTPSRTPSRSVSRTSLVSNPPGVNRVITREEFEAFVAQQQXRFDAGA (SEQ ID NO: 31)
Preparation of alphavirus replicon particles
10 μg of the full-length replicon plasmid prepared in Example 3, 1 μg of VEEV Env expression plasmid and 1 μg of VEEV Capsid NLS mutant (or 1 μg VEEV Capsid expression plasmid) was transfected into HEK293T cells. The supernatant was harvested 48-96 hours after transfection. The replicon particle was purified by using an ion exchange column. HET293T or Vero cells were infected with dilutions of the purified particle preparation to determine the infectious titer. The purified replicon particles are used for producing antigens for diagnosis and vaccination.
10 μg of the full-length replicon plasmid prepared in Example 3, 1 μg of VEEV Env expression plasmid and 1 μg of VEEV Capsid NLS mutant (or 1 μg VEEV Capsid expression plasmid) was transfected into HEK293T cells. The supernatant was harvested 48-96 hours after transfection. The replicon particle was purified by using an ion exchange column. HET293T or Vero cells were infected with dilutions of the purified particle preparation to determine the infectious titer. The purified replicon particles are used for producing antigens for diagnosis and vaccination.
Expression of RBD in HEK293T cells
293T cells (6.25x10^5 cells/well) were transfected with Fectopro transfection reagent (Polyplus) and 2ug of each Replicon plasmid. Western blotting was performed on the supernatant directly without purification of particles (left) or on cell lysate fractions (right) 72h after transfection using antisera reactive with Covid-19-RBD as a primary antibody and goat anti-rabbit immunoglobulins linked to horseradish peroxidase as a secondary antibody. Also Western blotting was performed for confirming the expression of antigen from Construct K and Construct O in the cell lysate fractions 72h after transfection using antisera reactive with Covid-19-RBD as a primary antibody and goat anti-rabbit immunoglobulins linked to horseradish peroxidase as a secondary antibody.
293T cells (6.25x10^5 cells/well) were transfected with Fectopro transfection reagent (Polyplus) and 2ug of each Replicon plasmid. Western blotting was performed on the supernatant directly without purification of particles (left) or on cell lysate fractions (right) 72h after transfection using antisera reactive with Covid-19-RBD as a primary antibody and goat anti-rabbit immunoglobulins linked to horseradish peroxidase as a secondary antibody. Also Western blotting was performed for confirming the expression of antigen from Construct K and Construct O in the cell lysate fractions 72h after transfection using antisera reactive with Covid-19-RBD as a primary antibody and goat anti-rabbit immunoglobulins linked to horseradish peroxidase as a secondary antibody.
The results are shown in Figure 3.
The abbreviation means as follows:
ssRBD: construct A
hIL-2ssRBD-TM: construct 1 (mouse HA)
ssRBD-linker-TM: construct C (TM1: mouse CD80, Linker: mouse IgG4-CH3)
The abbreviation means as follows:
ssRBD: construct A
hIL-2ssRBD-TM: construct 1 (mouse HA)
ssRBD-linker-TM: construct C (TM1: mouse CD80, Linker: mouse IgG4-CH3)
Mouse: CD80(TM-Cyt)
TLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRRNEASRETNNSLTFGPEEALAEQTVFL (SEQ ID NO: 32)
TLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRRNEASRETNNSLTFGPEEALAEQTVFL (SEQ ID NO: 32)
Mouse IgG4-CH3
GRPKAPQVYTIPPPKEQMAKDKVSLTCMITNFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 33)
GRPKAPQVYTIPPPKEQMAKDKVSLTCMITNFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 33)
Expressions were confirmed for all tested particles in the cells. As expected the ssRBD without a transmembrane sequence was secreted into the medium of the cell culture, whereas each of the RBD constructs linked to a transmembrane sequence was retained in the cells and not secreted into the media.
Immunogenicity
The following Replicon Particle Vaccines prepared in Example 4 were used.
VRep ssRBD: VEEV particle packaging construct A
VRep sshIL2 RBD HA: VEEVparticle packaging construct 1
VRep ssRBD mIgG4 CD80: VEEV Replicon particle packaging Construct C (TM1: mouse CD80, Linker: mouse IgG4-CH3)
Control: VEEV Replicon without gene of interest
DNA vaccine: DNA expressing the spike protein of COVID-19
The following Replicon Particle Vaccines prepared in Example 4 were used.
VRep ssRBD: VEEV particle packaging construct A
VRep sshIL2 RBD HA: VEEV
VRep ssRBD mIgG4 CD80: VEEV Replicon particle packaging Construct C (TM1: mouse CD80, Linker: mouse IgG4-CH3)
Control: VEEV Replicon without gene of interest
DNA vaccine: DNA expressing the spike protein of COVID-19
Mice were immunized intramuscularly three times (on Day0, Day7 and Day14) with the indicated Replicon particles (RBD or RBD-linker-TM, 10^7IU/dose), a control Replicon particle or a DNA vaccine (20ug/dose), and sera were collected on Day14 (7days after 2nd immunization) and Day35 (21 days after 3nd immunization). These sera were examined in ELISA assays performed against a COVID-19-Spike S1 or RBD antigen. The symbols show the average of the five mice in each group, and error bars show the s.e.m. The curve fit was calculated by Prism software. These results are shown in Figure 4 (4-1 and 4-2) and Figure 5 (5-1 and 5-2).
Figures 4 and 5 show that significantly higher titers of antibody against recombinant Coronavirus RBD and Spike S1 were achieved after immunization with replicon vaccines. In contrast, very low titers of antibody were induced with the DNA vaccine.
Immunogenicity
The following Replicon Particle Vaccines prepared in Example 4 were used.
CD80: VEEV particle packaging Construct C
HA No.1: VEEV particle packaging Construct K
Control: PBS
The following Replicon Particle Vaccines prepared in Example 4 were used.
CD80: VEEV particle packaging Construct C
HA No.1: VEEV particle packaging Construct K
Control: PBS
Mice were immunized intramuscularly with the indicated Replicon vaccines (CD80 or HA No.1, 10^5IU/dose) or PBS, and sera were collected 7 days after immunization. These sera were subject to ELISA analysis performed against a COVID-19-Spike S1 antigen. The symbols show the mean of the five mice in each group, and error bars show the s.e.m. These results are shown in Figure 6.
Figure 6 shows that significantly higher titers of antibody against recombinant Coronavirus Spike S1 were achieved after immunization with replicon vaccines.
Preparation of self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP)
The vector comprising the DNA sequence encoding construct C prepared in Example 3 was used. The DNA was linearized and used as the template. T7 in vitro transcription was conducted based on protocols provided by the T7 transcription kit (RiboMaxTM Express Large Scale RNA production System, Promega, (WI USA)). The linear DNA template was mixed with T7 enzyme and rNTPs to synthesize RNA. The purified RNA product was capped using vaccinia capping enzyme to give self-amplifying RNA.
The vector comprising the DNA sequence encoding construct C prepared in Example 3 was used. The DNA was linearized and used as the template. T7 in vitro transcription was conducted based on protocols provided by the T7 transcription kit (RiboMaxTM Express Large Scale RNA production System, Promega, (WI USA)). The linear DNA template was mixed with T7 enzyme and rNTPs to synthesize RNA. The purified RNA product was capped using vaccinia capping enzyme to give self-amplifying RNA.
The obtained saRNA was encapsulated in lipid nanoparticles to give saRNA(RBD-CD80TM) particles. Lipid nanoparticles with no RNA was used as control.
Immunization
saRNAs formulated with LNP prepared in Example 8 were used.
Amount of immunization:
0.3ug saRNA(RBD-CD80TM)
1ug saRNA(RBD-CD80TM)
10ug saRNA(RBD-CD80TM)
no RNA (control)
The indicated amount of saRNA or no RNA (control) formulated with LNP (Genvoy) were used. The 4-6 weeks old mice (n=5 per group) were immunized with saRNA formulated with LNP onDay 0 and Day 28 by intramuscularly injections.
saRNAs formulated with LNP prepared in Example 8 were used.
Amount of immunization:
0.3ug saRNA(RBD-CD80TM)
1ug saRNA(RBD-CD80TM)
10ug saRNA(RBD-CD80TM)
no RNA (control)
The indicated amount of saRNA or no RNA (control) formulated with LNP (Genvoy) were used. The 4-6 weeks old mice (n=5 per group) were immunized with saRNA formulated with LNP on
The mice were bleed on Day 14, 28 and 46. The antibody titer against S1 protein in the sera from the immunized mice were measured by ELISA. The plate were coated with S1 protein (Sinobio 100ng/ml). Results are shown in Figure 6.
The COVID-19 RBD may be derived from COVID-19 mutants. The following amino acid sequences of constructions comprising the COVID-19 signal sequence, COVID-19 RBD derived from a COVID-19 mutant, and human HA(flexible-TM-Cyt) are also used for generating alphavirus replicon as shown in Figure 1. In this example the gene of interest is replaced with the polynucleotide encoding the following amino acid sequence. Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) is generated in the same manner as Example 8.
Construct derived from COVID-19 E484K_N501Y_K417T mutant (Brazil Strain Mutant) MFVFLVLLPLVSSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGTIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 34)
Construct derived from COVID-19 E484K_N501Y_K417N mutant (South African Mutant)
MFVFLVLLPLVSSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 35)
MFVFLVLLPLVSSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO: 35)
Construct derived from COVID-19 E484K mutant
MFVFLVLLPLVSSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO 36)
MFVFLVLLPLVSSVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI (SEQ ID NO 36)
Claims (30)
- An isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain.
- The polynucleotide of Claim 1, wherein the coronavirus protein is a spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, small envelope (E) protein or a combination thereof.
- The polynucleotide of Claim 1, wherein the coronavirus protein is a spike (S) protein.
- The polynucleotide of Claim 1, wherein the coronavirus protein is a S1 and/or S2 subunit of a spike (S) protein.
- The polynucleotide of Claim 4, wherein the coronavirus protein is a S1 subunit in a spike (S) protein.
- The polynucleotide of Claim 5, wherein the coronavirus protein is a receptor binding domain of the S1 subunit.
- The polynucleotide of any one of Claims 1-6, wherein the transmembrane domain is derived from Influenza Hemagglutinin (HA), CD80 or TLR4.
- The polynucleotide any one of Claims 1-6, wherein the transmembrane domain is a modified transmembrane domain derived from coronavirus structural protein.
- The polynucleotide of Claim 8, the modified transmembrane domain comprises juxtamembrane domain and transmembrane domain of COVID-19 Spike (S).
- The polynucleotide of any one of Claims 1-9, wherein coronavirus protein is fused to a signal sequence and transmembrane domain.
- The polynucleotide of any one of Claims 1-10, wherein the signal sequence is derived from human IL-2.
- The polynucleotide of any one of Claim 1-10, wherein the signal sequence is derived from COVID-19 spike protein.
- The polynucleotide of any one of Claims 1-12, wherein the transmembrane domain and/or signal sequence is fused to the coronavirus protein by a linker.
- The polynucleotide of Claim 13 wherein the linker is IgG4CH3 and/or short linker.
- The polynucleotide of any one of Claims 1-14, wherein the coronavirus is COVID-19.
- The polynucleotide of Claim 15, wherein the polypeptide encodes an amino acid sequence selected from SEQ ID NOs 1, 5, 6, 8, 9, 11, 12, 13, 34, 35 and 36.
- The polynucleotide of Claim 15, wherein the polypeptide encodes an amino acid sequence selected from SEQ ID NOs 37-51.
- The polynucleotide of any one of claims 1 to 17, wherein the polynucleotide is RNA.
- The polynucleotide of any one of Claims 1 to 17, wherein the polynucleotide is DNA.
- A vector comprising the polynucleotide of any one of Claims 1 to 19.
- The vector of Claim 20, which comprises a promoter, 5' UTR, polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, SG promoter, a gene of interest encoding the polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain, 3'UTR and poly A tail.
- A vaccine composition comprising the polynucleotide or vector of any one of Claims 1 to 21 and a pharmaceutically acceptable carrier.
- The vaccine composition of Claim 22, wherein the pharmaceutically acceptable carrier is a delivery vehicle.
- The vaccine composition of Claim 23, wherein the delivery vehicle is a particle consisting of one or more alphavirus structural proteins or a lipid delivery system.
- Use of the polynucleotide or vector of any one of claims 1-21 for the manufacture of a medicament.
- Use of claim 25, wherein the medicament is for inducing immunomodulation in a subject.
- Use of claim 25, wherein the medicament is for treating or preventing a subject from conditions caused by coronavirus infection.
- A method of immunomodulation in a subject, comprising administering an immunologically effective amount of the vaccine composition of any one of Claims 22 to 24 to the subject in need thereof.
- A method of treating, preventing and/or immunizing against coronavirus viral infection in a subject, comprising administering an effective amount of the vaccine composition of any one of Claims 22 to 24 to the subject in need thereof.
- A polypeptide comprising a coronavirus structural protein fused to a signal sequence and/or heterologous transmembrane domain.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022562739A JP2023523580A (en) | 2020-04-17 | 2021-04-16 | coronavirus vaccine |
EP21788260.4A EP4135847A1 (en) | 2020-04-17 | 2021-04-16 | Coronavirus vaccine |
CN202180028581.8A CN115867658A (en) | 2020-04-17 | 2021-04-16 | Coronavirus vaccine |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011561P | 2020-04-17 | 2020-04-17 | |
US63/011,561 | 2020-04-17 | ||
US202063050442P | 2020-07-10 | 2020-07-10 | |
US63/050,442 | 2020-07-10 | ||
US202063088723P | 2020-10-07 | 2020-10-07 | |
US63/088,723 | 2020-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021210686A1 true WO2021210686A1 (en) | 2021-10-21 |
Family
ID=78082332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/015773 WO2021210686A1 (en) | 2020-04-17 | 2021-04-16 | Coronavirus vaccine |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210322541A1 (en) |
EP (1) | EP4135847A1 (en) |
JP (1) | JP2023523580A (en) |
CN (1) | CN115867658A (en) |
TW (1) | TW202204623A (en) |
WO (1) | WO2021210686A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112029781A (en) * | 2020-08-14 | 2020-12-04 | 中山大学 | Novel coronavirus SARS-CoV-2 safety replicon system and application thereof |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11654200B2 (en) | 2020-03-23 | 2023-05-23 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202338090A (en) * | 2021-12-17 | 2023-10-01 | 日商Vlp醫療日本股份有限公司 | Efficient vaccine |
WO2023220693A1 (en) * | 2022-05-12 | 2023-11-16 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
WO2023234300A1 (en) * | 2022-05-31 | 2023-12-07 | Vlp Therapeutics Japan, Inc. | Modified vaccine design developments |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009009215A2 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
CN104293740A (en) * | 2013-07-18 | 2015-01-21 | 特菲(天津)生物医药科技有限公司 | Recombinant baculovirus with surface displaying SARS bivalent antigen, and preparation method and application thereof |
US20150299728A1 (en) * | 2004-05-18 | 2015-10-22 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
CN106928372A (en) * | 2016-12-30 | 2017-07-07 | 北京大学深圳研究生院 | Hepatitis B recombinant antigen and its expressing gene, construction method, virus-like particle and preparation method thereof, using with vaccine |
US20190185822A1 (en) | 2017-12-20 | 2019-06-20 | Vlp Therapeutics, Llc | Alphavirus replicon particle |
RU2733832C1 (en) * | 2020-07-28 | 2020-10-07 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Artificial gene stbl_rbd_trm_sc2, coding a bicistronic structure formed by the sars-cov-2 coronavirus glycoprotein s receptor-binding domain sequences, transmembrane region, p2a-peptide and glycoprotein g vsv, recombinant plasmid pstem-rvsv-stbl_rbd_trm_sc2, providing expression of artificial gene, and a recombinant strain of vesicular stomatitis virus rvsv-stbl_rbd_trm_sc2, used to create a vaccine against sars-cov-2 coronavirus |
-
2021
- 2021-04-16 US US17/232,666 patent/US20210322541A1/en active Pending
- 2021-04-16 TW TW110113785A patent/TW202204623A/en unknown
- 2021-04-16 EP EP21788260.4A patent/EP4135847A1/en active Pending
- 2021-04-16 WO PCT/JP2021/015773 patent/WO2021210686A1/en unknown
- 2021-04-16 JP JP2022562739A patent/JP2023523580A/en active Pending
- 2021-04-16 CN CN202180028581.8A patent/CN115867658A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150299728A1 (en) * | 2004-05-18 | 2015-10-22 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
WO2009009215A2 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
CN104293740A (en) * | 2013-07-18 | 2015-01-21 | 特菲(天津)生物医药科技有限公司 | Recombinant baculovirus with surface displaying SARS bivalent antigen, and preparation method and application thereof |
CN106928372A (en) * | 2016-12-30 | 2017-07-07 | 北京大学深圳研究生院 | Hepatitis B recombinant antigen and its expressing gene, construction method, virus-like particle and preparation method thereof, using with vaccine |
US20190185822A1 (en) | 2017-12-20 | 2019-06-20 | Vlp Therapeutics, Llc | Alphavirus replicon particle |
RU2733832C1 (en) * | 2020-07-28 | 2020-10-07 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Artificial gene stbl_rbd_trm_sc2, coding a bicistronic structure formed by the sars-cov-2 coronavirus glycoprotein s receptor-binding domain sequences, transmembrane region, p2a-peptide and glycoprotein g vsv, recombinant plasmid pstem-rvsv-stbl_rbd_trm_sc2, providing expression of artificial gene, and a recombinant strain of vesicular stomatitis virus rvsv-stbl_rbd_trm_sc2, used to create a vaccine against sars-cov-2 coronavirus |
Non-Patent Citations (12)
Title |
---|
AGNIHOTHRAM SUDHAKAR, MENACHERY VINEET D., YOUNT BOYD L., LINDESMITH LISA C., SCOBEY TREVOR, WHITMORE ALAN, SCHÄFER ALEXANDRA, HEI: "Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 92, no. 11, 1 June 2018 (2018-06-01), US , XP055858879, ISSN: 0022-538X, DOI: 10.1128/JVI.00027-18 * |
HETRICK BRIAN, HE SIJIA, CHILIN LINDA D., DABBAGH DEEMAH, ALEM FARHANG, NARAYANAN AARTHI, LUCHINI ALESSANDRA, LI TUANJIE, LIU XUEF: "Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs", BIORXIV, 5 May 2021 (2021-05-05), XP055858887, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.12.22.423965v2.full.pdf> DOI: 10.1101/2020.12.22.423965 * |
HOWARD ET AL., JOURNAL OF VIROLOGY, vol. 82, no. 6, March 2008 (2008-03-01), pages 2883 - 2894 |
KINNEY R. M., ET AL.: "ATTENUATION OF VENEZUELAN EQUINE ENCEPHALITIS VIRUS STRAIN TC-83 IS ENCODED BY THE 5'-NONCODING REGION AND THE E2 ENVELOPE GLYCOPROTEIN.", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 67., no. 03., 1 March 1993 (1993-03-01), US , pages 1269 - 1277., XP002041259, ISSN: 0022-538X * |
M. W. HOWARD, E. A. TRAVANTY, S. A. JEFFERS, M. K. SMITH, S. T. WENNIER, L. B. THACKRAY, K. V. HOLMES: "Aromatic Amino Acids in the Juxtamembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Are Important for Receptor-Dependent Virus Entry and Cell-Cell Fusion", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 6, 15 March 2008 (2008-03-15), US , pages 2883 - 2894, XP055430357, ISSN: 0022-538X, DOI: 10.1128/JVI.01805-07 * |
OZHAROVSKAIA T. A., ZUBKOVA O. V., DOLZHIKOVA I. V., GROMOVA A. S., GROUSOVA D. M., TUKHVATULIN A. I., POPOVA O., SHCHEBLYAKOV D. : "Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein", ACTA NATURAE, PARK MEDIA, RU, vol. 11, no. 1, 1 March 2019 (2019-03-01), RU , pages 38 - 47, XP055858884, ISSN: 2075-8251, DOI: 10.32607/20758251-2019-11-1-38-47 * |
P. H. POUWELS ET AL.: "Cloning Vectors: A Laboratory Manual", 1985 |
See also references of EP4135847A1 |
T. SHEAHAN, A. WHITMORE, K. LONG, M. FERRIS, B. ROCKX, W. FUNKHOUSER, E. DONALDSON, L. GRALINSKI, M. COLLIER, M. HEISE, N. DAVIS, : "Successful Vaccination Strategies That Protect Aged Mice from Lethal Challenge from Influenza Virus and Heterologous Severe Acute Respiratory Syndrome Coronavirus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 85, no. 1, 1 January 2011 (2011-01-01), US , pages 217 - 230, XP055752333, ISSN: 0022-538X, DOI: 10.1128/JVI.01805-10 * |
WRAPP ET AL., SCIENCE 10.1126/SCIENCE.ABB2507, 2020 |
YE V. LIU; MICHAEL J. MASSARE; DALE L. BARNARD; THOMAS KORT; MARGRET NATHAN; LEI WANG; GALE SMITH;: "Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 38, 29 June 2011 (2011-06-29), AMSTERDAM, NL , pages 6606 - 6613, XP028265259, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2011.06.111 * |
Z. WANG ET AL., BIORXIV 2021.01.15.426911, Retrieved from the Internet <URL:https://doi.org/10.1101/2021.01.15.426911> |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11654200B2 (en) | 2020-03-23 | 2023-05-23 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11752218B2 (en) | 2020-03-23 | 2023-09-12 | Hdt Bio Corp. | Nucleic acid-small diameter and liquid core nanoparticle complexed compositions |
US11896677B2 (en) | 2020-03-23 | 2024-02-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11951185B2 (en) | 2020-04-22 | 2024-04-09 | BioNTech SE | RNA constructs and uses thereof |
CN112029781A (en) * | 2020-08-14 | 2020-12-04 | 中山大学 | Novel coronavirus SARS-CoV-2 safety replicon system and application thereof |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Publication number | Publication date |
---|---|
JP2023523580A (en) | 2023-06-06 |
US20210322541A1 (en) | 2021-10-21 |
TW202204623A (en) | 2022-02-01 |
EP4135847A1 (en) | 2023-02-22 |
CN115867658A (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021210686A1 (en) | Coronavirus vaccine | |
US20230270841A1 (en) | Coronavirus vaccine | |
US20180000912A1 (en) | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity | |
KR20200037818A (en) | Methods and compositions for heterologous repRNA immunization | |
US20220002682A1 (en) | Alphavirus replicon particle | |
US20230256083A1 (en) | Self-amplifying sars-cov-2 rna vaccine | |
WO2023113016A1 (en) | Efficient vaccine | |
WO2023234300A1 (en) | Modified vaccine design developments | |
AU2022326491A1 (en) | Vaccine antigen | |
TW202408543A (en) | Modified vaccine design developments | |
US20210340567A1 (en) | Cytokine immunotherapy | |
CN117860880A (en) | RdRp-dependent African swine fever taRNA vaccine and construction method and application thereof | |
OA20123A (en) | Alphavirus replicon particle. | |
WO2023023674A2 (en) | Coronavirus vaccine formulations incorporating prime and boost |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21788260 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022562739 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021788260 Country of ref document: EP Effective date: 20221117 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |